Engineered migrasomes, methods for producing same, and uses thereof

Engineered migrasomes, produced by inducing cell movement and overexpressing tetraspanin proteins, address biocompatibility and production challenges of existing systems, offering low toxicity and high capacity for diverse cargo delivery in drug and vaccine applications.

JP2024541545APending Publication Date: 2024-11-08BEIJING MIGRASOME THERAPEUTICS LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024531457
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-25
Filing Date
2022-11-24
Publication Date
2024-11-08

Smart Images

  • Figure 2024541545000009
    Figure 2024541545000009
  • Figure 2024541545000010
    Figure 2024541545000010
  • Figure 2024541545000011
    Figure 2024541545000011
Patent Text Reader

Abstract

Engineered migrasomes, methods for their production and uses are provided, in particular including a method for producing migrasomes, which comprises moving cells relative to one another to produce migrasomes derived from said cells. Also provided are migrasomes produced by the method, migrasomes produced in vitro or ex vivo, and delivery systems comprising said migrasomes.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the field of biomedicine, and in particular to engineered migrasomes, methods of making engineered migrasomes, delivery systems comprising engineered migrasomes, and methods of making the delivery systems. [Background technology]

[0002] There are many problems with the existing delivery systems in the art. For example, biological nanoparticle and microparticle delivery systems have high biocompatibility and relatively good targeting ability, but are difficult to produce; engineered exosomes show obvious limitations such as low production yield, need for ultracentrifugation during purification, and cargo mainly limited to nucleic acids loaded after production; engineered red blood cells require blood samples for each production, since they cannot be continuously cultured or grown in vitro; red blood cells are also very limited to cargo types that mainly contain nucleic acids; membrane-modified nanoparticles are difficult to eliminate by the normal metabolism of the human body, so they may accumulate in the body and exhibit potential toxicity; cargo that can be delivered by viruses and virus-like particles is basically limited to nucleic acids and low molecular weight proteins, but the production and purification of viruses and virus-like particles is difficult and expensive, and difficult to modify, etc. Therefore, there is a need in the art for a new delivery system that can overcome one or more of the shortcomings present in the existing drug delivery systems.

[0003] In the present application, it has been found that the generation of engineered migrasomes, which are similar in structure to natural migrasomes, can be induced by various methods, and these engineered migrasomes are different from the "hypotonicity-induced vesicles" known in the art. In the present application, it has been found that the engineered migrasomes are of biological origin with the advantages of low toxicity and low immunogenicity; the engineered migrasomes are newly discovered extracellular vesicles with unique advantages in cargo molecule type and in vivo biodistribution; and at the same time, the method of producing engineered migrasomes is high-yield and simple. Therefore, the engineered migrasomes provided by the present application have very high application value in biomedical fields such as drug delivery and vaccine production. Summary of the Invention [Means for solving the problem]

[0004] The present application provides engineered migrasomes, methods for producing engineered migrasomes, delivery systems including engineered migrasomes, and methods for producing delivery systems. Engineered migrasomes have the following advantages, including but not limited to low toxicity, low immunogenicity, the ability to deliver a variety of exogenous cargo molecules, suitable biodistribution in vivo, simple preparation methods, and / or high yields. The engineered migrasomes provided by the present application can be used for drug delivery, vaccine preparation, and the like, with excellent effects.

[0005] In one aspect, the present application provides a method of making migrasomes comprising moving cells relative to one another to produce migrasomes derived from the cells.

[0006] In a method according to one embodiment, the method further comprises isolating migrasomes produced by the cells.

[0007] In a method according to one embodiment, the method comprises subjecting the cells to a hypotonic treatment.

[0008] In a method according to one embodiment, the hypotonic treatment comprises placing the cells in a hypotonic buffer.

[0009] In a method according to one embodiment, the hypotonic treatment comprises placing the cells in a buffer and reducing the osmolarity of the buffer to make it a hypotonic buffer.

[0010] In a method according to an embodiment, the decrease comprises a linear decrease and / or a stepwise decrease.

[0011] In one embodiment of the method, the hypotonic buffer has an osmolality of less than about 305 mOsmol / L.

[0012] In one embodiment of the method, the hypotonic buffer has an osmolality of about 10 mOsmol / L to about 274.5 mOsmol / L.

[0013] In a method according to one embodiment, the method comprises disrupting the cytoskeleton of the cell.

[0014] In a method according to one embodiment, disrupting the cytoskeleton of the cell comprises contacting the cell with a cytoskeleton disrupting reagent.

[0015] In a method according to one embodiment, the cytoskeleton disrupting reagent comprises a microfilament and / or microtubule depolymerizing agent.

[0016] In a method according to one embodiment, the cytoskeleton disruption reagent comprises latrunculin A, latrunculin B, cytochalasin A, cytochalasin B, cytochalasin C, cytochalasin D, and / or cytochalasin E.

[0017] In a method according to one embodiment, the method comprises inhibiting a cell volume regulatory function of the cell.

[0018] In a method according to one embodiment, inhibiting a cell volume regulatory function of a cell comprises decreasing the number and / or function of volume regulatory proteins in the cell.

[0019] In a method according to one embodiment, the volume regulatory protein comprises a volume-regulatory ion channel and / or transporter.

[0020] In a method according to one embodiment, the volume-regulated ion channel comprises a volume-regulated anion channel VRAC and / or a volume-regulated cation channel VRCC.

[0021] In a method according to one embodiment, the volume-regulatory anion channel VRAC comprises SWELL1 or a functionally active fragment thereof.

[0022] In a method according to one embodiment, the volume-regulated cation channel VRCC comprises TRPV4, TRPM3, and / or functionally active fragments thereof.

[0023] In a method according to one embodiment, the transporter comprises a cotransporter.

[0024] In a method according to one embodiment, the co-transporter comprises KCC1, KCC3, and / or KCC4.

[0025] In one embodiment of the method, inhibiting the cell volume regulatory function of the cells comprises placing the cells in a buffer that can inhibit the volume regulatory ability of the cells.

[0026] In a method according to one embodiment, the buffer contains increased cations.

[0027] In a method according to one embodiment, the cation is K + , Na + , Cs + , Li + , Ca 2+ , Mg 2+ , B.A. 2+ , Mn 2+ , Fe 2+ , Ni 2+ , Zn 2+ , Al 3+ , Fe 3+ , CH3NH3 + , C2H5NH3+ , (CH3)2NH2 + , (C2H5)2NH2 + , (C2H5)3N + , ammonium ions, and / or choline ions.

[0028] In a method according to one embodiment, the buffer comprises increased anions.

[0029] In a method according to one embodiment, the anion is Br - , Cl - , I - , F - , O.H. - , HCO3 - , H2PO4 - , NO2 - , NO3 - , C.N. - , HPO4 2- , CO3 2- , SO4 2- , and / or PO4 3- Includes.

[0030] In a method according to one embodiment, the method includes detaching the cells from the surface to which they are attached.

[0031] In a method according to one embodiment, the method comprises causing a relative movement between a cell membrane of the cell and the adherent surface.

[0032] In a method according to one embodiment, the method further comprises increasing the number and / or function of tetraspanin proteins, functional fragments thereof, and / or functional variants thereof in the cell.

[0033] In a method according to one embodiment, the method comprises causing a cell to overexpress a tetraspanin protein, a functional fragment thereof, and / or a functional variant thereof.

[0034] In a method according to one embodiment, the tetraspanin protein is Tspan1, Tspan2, Tspan3, Tspan4, Tspan5, Tspan6, Tspan7, Tspan8, Tspan9, Tspan10, Tspan11, Tspan12, Tspan13, Tspan14, Tspan15, Tspan16, Tspan17, Tspan18, Tspan19, Tspan20 (UP K1B), Tspan21 (UPK1A), Tspan22 (PRPH2), Tspan23 (ROM1), Tspan24 (CD151), Tspan25 (CD53), Tspan26 (CD37), Tspan27 (CD82), Tspan28 (CD81), Tspan29 (CD9), Tspan30 (CD63), Tspan31, Tspan32, and Tspan33.

[0035] In a method according to one embodiment, the method further comprises reducing the size of the migrasomes.

[0036] In a method according to one embodiment, reducing the size of the migrasomes includes extruding the migrasomes through a filter or an extruder.

[0037] In a method according to one embodiment, the filter or extruder has a pore size of about 30 nm to about 10,000 nm.

[0038] In one embodiment of the method, the migrasomes have a size of about 50 nm to about 8000 nm.

[0039] In one embodiment of the method, migrasomes are generated from retraction fibers of cells.

[0040] In a method according to one embodiment, the membrane of the migrasome is enriched with sodium / potassium ATPase and / or a functional fragment thereof.

[0041] In a method according to one embodiment, the membrane of the migrasome is enriched with integrins and / or functional fragments thereof.

[0042] In a method according to one embodiment, the membrane of the migrasome is enriched with a tetraspanin protein, a functional variant thereof, and / or a functional fragment thereof.

[0043] In one embodiment of the method, the membrane of the migrasomes is enriched with cholesterol.

[0044] In a method according to one embodiment, migrasomes are enriched in membrane microdomains.

[0045] In a method according to one embodiment, migrasomes are produced in vitro or ex vivo.

[0046] In a method according to one embodiment, the content of migrasomes is at least partially reduced or absent compared to native migrasomes produced by the corresponding cells.

[0047] In a method according to one embodiment, the at least partially reduced contents include intraluminal vesicles.

[0048] In a method according to one embodiment, the method is an in vitro method or an ex vivo method.

[0049] In a method according to one embodiment, the cells are in vitro cultured cells.

[0050] In the method according to one embodiment, the cells are suspension cultured cells or adherent cultured cells.

[0051] In the method according to one embodiment, the cells comprise primary cells.

[0052] In a method according to one embodiment, the primary cells include tissue cells derived from organisms including human, monkey, mouse, rat, rabbit, chicken, and / or insect.

[0053] In a method according to one embodiment, the primary cells include liver cells, spleen cells, kidney cells, tissue macrophages, brain glial cells, osteoclasts, bone marrow cells, leukocytes, fibroblasts, and / or adipocytes.

[0054] In a method according to one embodiment, the leukocytes include B cells, T cells, NK cells, dendritic cells, neutrophils, and / or macrophages.

[0055] In the method according to one embodiment, the cells comprise tumor cells.

[0056] In one embodiment of the method, the tumor cells include tumor cell lines, primary or restricted passage tumor cells derived from a patient, tumor stromal cells, and / or tumor organoids.

[0057] In a method according to one embodiment, the cells include CHO cells, CHO-K1 cells, HEK293 cells, HEK293T cells, HEK293FT cells, HEK293F cells, Vero cells, NRK cells, L929 cells, MC38 cells, 4T1 cells, DC2.4 cells, MGC803 cells, Jurkat cells, NK-92MI cells, BJ cells, and / or HepG2 cells.

[0058] In the method according to one embodiment, the cells include white blood cells, stem cells, and / or fibroblasts.

[0059] In the method according to one embodiment, the stem cells comprise mesenchymal stem cells.

[0060] In a method according to one embodiment, migrasomes are produced.

[0061] In another aspect, the present application provides migrasomes produced in vitro or ex vivo, the migrasomes having a size of about 50 nm to about 8000 nm.

[0062] In one embodiment of the migrasomes, the migrasomes are produced in vitro from retraction fibers of cells.

[0063] In a migrasome according to one embodiment, the membrane of the migrasome is enriched with sodium / potassium ATPase and / or functional fragments thereof.

[0064] In one embodiment of the migrasome, the membrane of the migrasome is enriched with integrins and / or functional fragments thereof.

[0065] In a migrasome according to one embodiment, the membrane of the migrasome is enriched with tetraspanin proteins, functional variants thereof, and / or functional fragments thereof.

[0066] In one embodiment of the migrasome, the membrane of the migrasome is enriched with cholesterol.

[0067] In one embodiment of the migrasomes, the migrasomes are enriched in membrane microdomains.

[0068] In one embodiment of the migrasomes, the migrasome content is at least partially reduced or absent compared to native migrasomes produced by the corresponding cells.

[0069] In one embodiment of the migrasome, the at least partially reduced contents include intraluminal vesicles.

[0070] In another aspect, the present application provides the use of migrasomes in the delivery of exogenous cargo.

[0071] In one embodiment of the use, the migrasomes include the migrasomes of the present application.

[0072] In another aspect, the present application provides a delivery system comprising migrasomes and one or more exogenous cargoes.

[0073] In one embodiment of the delivery system, the exogenous cargo is incorporated, conjugated, or intercalated, directly or indirectly, into the membrane and / or interior of the migrasome.

[0074] In one embodiment of the delivery system, the migrasomes comprise the migrasomes of the present application.

[0075] In one embodiment of the delivery system, the migrasomes are derived from cells.

[0076] In one embodiment of the delivery system, the exogenous cargo comprises one or more targeting agents and / or therapeutically active agents.

[0077] In one embodiment of the delivery system, the exogenous cargo comprises a protein, a lipid, a polynucleotide, a small molecule compound, a complex, a polysaccharide, a polymer, a nanoparticle, a microparticle, and / or an organelle.

[0078] In one embodiment of the delivery system, the exogenous cargo comprises a membrane protein, a soluble protein, and / or a polypeptide.

[0079] In one embodiment of the delivery system, the exogenous cargo comprises DNA and / or RNA.

[0080] In one embodiment of the delivery system, the exogenous cargo comprises an antibody or antigen-binding antibody fragment thereof, an integrin or fragment thereof, an immunogenic protein, a cytokine, a chemokine, a receptor protein or fragment thereof, an enzyme, a tumor suppressor gene product, an siRNA, a microRNA, an antisense oligonucleotide (ASO), an mRNA, a DNA, a gene editing tool, and / or a cytotoxic agent.

[0081] In one embodiment of the delivery system, the exogenous cargo comprises a PAMP, a DAMP, CD47, CD24, IL-12, IL-15, coagulation factor VII, coagulation factor VIII, coagulation factor IX, and / or a functionally active fragment thereof.

[0082] In one embodiment of the delivery system, the exogenous cargo is incorporated into the migrasome directly or indirectly by gene editing, exogenous expression, liquid-solid conversion, membrane fusion, charge adsorption, physical adsorption, and / or chemical conjugation.

[0083] In one embodiment of the delivery system, the exogenous cargo is incorporated or intercalated into the migrasome by direct or indirect conjugation to a membrane component of the migrasome.

[0084] In one embodiment of the delivery system, the membrane components of the migrasomes include membrane proteins, cholesterol, phospholipids, carbohydrate chains on glycoproteins, and / or polysaccharides.

[0085] In one embodiment of the delivery system, the indirect conjugation comprises binding via click chemistry.

[0086] In a delivery system according to one embodiment, indirect conjugation comprises providing an exogenous cargo conjugated to a first member of a binding pair and contacting the exogenous cargo with a migrasome, the membrane of which comprises a second member of the binding pair and the first member is capable of binding to the second member.

[0087] In the delivery system according to one embodiment, the first and second members of the binding pair are selected from an antigen and its antibody; a receptor and its ligand; biotin and avidin; HaloTag and its ligand; and CP05 and CD63.

[0088] In one embodiment of the delivery system, the exogenous cargo is expressed as a membrane protein on the inner or outer surface of the migrasome membrane.

[0089] In one embodiment of the delivery system, the exogenous cargo is expressed on the inner or outer membrane of the migrasome as a fusion protein fused to a membrane protein or portion thereof.

[0090] In one embodiment of the delivery system, the exogenous cargo is expressed on the inner or outer surface of the migrasome membrane as a fusion protein fused to a membrane protein or portion thereof by gene editing and / or exogenous expression.

[0091] In another aspect, the present application provides a method of making a delivery system, the method comprising providing a migrasome and loading the migrasome with an exogenous cargo.

[0092] In a method according to one embodiment, the migrasomes are isolated or purified migrasomes.

[0093] In one embodiment of the method, loading migrasomes with exogenous cargo comprises directly or indirectly incorporating or intercalating the exogenous cargo into the membrane and / or interior of the migrasome.

[0094] In a method according to one embodiment, the method further comprises isolating or purifying the migrasomes from the cells.

[0095] In one embodiment, the method includes providing a complex of an exogenous cargo and a first member of a binding pair, causing a cell to produce a migrasome that includes a second member of the binding pair, and contacting the migrasome with the complex to form a delivery system.

[0096] In a method according to one embodiment, the migrasomes include the migrasomes of the present application.

[0097] In a method according to one embodiment, the migrasomes are derived from a cell.

[0098] In a method according to one embodiment, the exogenous cargo comprises one or more targeting agents and / or therapeutically active agents.

[0099] In a method according to one embodiment, the exogenous cargo comprises a protein, a lipid, a polynucleotide, a small molecule compound, a complex, a polysaccharide, a polymer, a nanoparticle, a microparticle, and / or an organelle.

[0100] In a method according to one embodiment, the exogenous cargo comprises a membrane protein, a soluble protein, and / or a polypeptide.

[0101] In a method according to one embodiment, the exogenous cargo comprises DNA and / or RNA.

[0102] In a method according to one embodiment, the exogenous cargo comprises an antibody or antigen-binding antibody fragment thereof, an integrin or fragment thereof, an immunogenic protein, a cytokine, a chemokine, a receptor protein or fragment thereof, an enzyme, a tumor suppressor gene product, an siRNA, a microRNA, an antisense oligonucleotide (ASO), an mRNA, DNA, a gene editing tool, and / or a cytotoxic agent.

[0103] In a method according to one embodiment, the exogenous cargo comprises a PAMP, a DAMP, CD47, CD24, IL-12, IL-15, coagulation factor VII, coagulation factor VIII, coagulation factor IX, and / or a functionally active fragment thereof.

[0104] In one embodiment of the method, the exogenous cargo is incorporated into the migrasome directly or indirectly by gene editing, exogenous expression, liquid-solid conversion, membrane fusion, charge adsorption, physical adsorption, and / or chemical conjugation.

[0105] In a method according to one embodiment, the exogenous cargo is incorporated or intercalated into the migrasome by direct or indirect conjugation to a membrane component of the migrasome.

[0106] In a method according to one embodiment, the membrane components of the migrasome include membrane proteins, cholesterol, phospholipids, carbohydrate chains on glycoproteins, and / or polysaccharides.

[0107] In a method according to one embodiment, the indirect conjugation comprises binding via click chemistry.

[0108] In a method according to one embodiment, indirect conjugation comprises providing an exogenous cargo conjugated to a first member of a binding pair and contacting the exogenous cargo with a migrasome, the membrane of which comprises a second member of the binding pair and the first member is capable of binding to the second member.

[0109] In a method according to one embodiment, the first and second members of the binding pair are selected from an antigen and its antibody; a receptor and its ligand; biotin and avidin; HaloTag and its ligand; and CP05 and CD63.

[0110] In one embodiment of the method, the exogenous cargo is expressed as a membrane protein on the inner or outer surface of the membrane of the migrasome.

[0111] In one embodiment of the method, the exogenous cargo is expressed on the inner or outer membrane surface of the migrasome as a fusion protein fused to a membrane protein or portion thereof.

[0112] In another aspect, the application provides a method of making a delivery system, comprising: causing a cell to express an mRNA; causing the cell to produce a migrasome comprising an mRNA-binding protein; and binding the mRNA to the migrasome via the mRNA-binding protein.

[0113] In another aspect, the application provides a method of making a delivery system, the method comprising: causing a cell to express an exogenous cargo on the cell membrane; and causing the cell to produce migrasomes comprising the exogenous cargo.

[0114] In a method according to one embodiment, the exogenous cargo is a protein.

[0115] In a method according to one embodiment, the protein is a membrane protein.

[0116] In a method according to one embodiment, the protein is a soluble protein and is fused to a membrane protein or portion thereof to form a fusion protein.

[0117] In another aspect, the present application provides a composition comprising the migrasomes of the present application or the delivery system of the present application.

[0118] Other aspects and advantages of the present application can be readily recognized by those skilled in the art from the following detailed description. The following detailed description merely illustrates and describes exemplary embodiments of the present application. As will be understood by those skilled in the art, the contents of the present application will enable those skilled in the art to modify the specific embodiments disclosed without departing from the principles and scope contained in the present application. Accordingly, the accompanying drawings and the description herein are for illustrative purposes only and not for limiting purposes.

[0119] Particular features of the invention contained in this application are recited in the appended claims. The features and advantages of the invention contained in this application may be better understood with reference to the exemplary embodiments described in detail below and the accompanying drawings, which are briefly described as follows: [Brief description of the drawings]

[0120] [Figure 1] Figure 1 shows the effect of hypotonic stimulation on the formation of engineered migrasomes. a: Formation of engineered migrasomes at different time points under hypotonic stimulation at 76.3 mOsmol / L (scale: 5 μm). b: Formation of engineered migrasomes at different osmolarity. c: Statistical results of diameter of engineered migrasomes shown in b. [Diagram 2]Figure 1 shows the effect of treatment with different concentrations of latrunculin A on the formation of engineered migrasomes: a: Formation of engineered migrasomes at different concentrations of latrunculin A. b: Statistical results of the number of engineered migrasomes shown in a. [Diagram 3] Figure 1 shows the effect of knockdown of the gene Lrrc8a encoding SWELL1 in cells on the formation of engineered migrasomes. a: Knockdown efficiency of Lrrc8a in cells determined by qPCR. b: Engineered migrasomes produced by stepwise hypotonic stimulation of cells with Lrrc8a knockdown observed using a laser confocal microscope. c: Statistical results of the diameter of engineered migrasomes shown in b. [Figure 4] Figure 1 shows the effect of knockout of the gene Lrrc8a encoding SWELL1 in cells on the formation of engineered migrasomes. a: Knockout of Lrrc8a in cells determined by Western blotting. b: Engineered migrasomes produced by stepwise hypotonic stimulation of cells with Lrrc8a knockout observed using laser confocal microscopy. [Diagram 5] Figure 1 shows the effect of treatment with different cations on the formation of engineered migrasomes: a: Formation of engineered migrasomes with different cations in the reaction solution, b: Statistical results of the diameter of engineered migrasomes shown in a. [Figure 6] Figure 1 shows the effect of overexpression of Tspan4 on the number of engineered migrasomes: a: Formation of engineered migrasomes in the presence of overexpression of Tspan4, b: Statistical results of the number of engineered migrasomes shown in a. [Figure 7] Figure 1 shows migrasomes produced by MGC803-T4-GFP cells in temperature-sensitive coated culture dishes. a: Photographs of migrasomes produced by MGC803-T4-GFP cells in different culture dishes under different conditions. b: Quantification of cell detachment rate. [Figure 8]Figure 1. Engineered migrasomes induced in different cell lines. a: Engineered migrasomes induced in different rodent cell lines. b: Enlargement of selected area from a (scale: 5 μm). c: Engineered migrasomes induced in two T4-GFP transfected human embryonic kidney cell lines / systems. d: Engineered migrasomes induced in different human cell lines stained with WGA. [Figure 9] FIG. 1 shows differentially induced engineered migrasomes in NRK cells (a) and MC38 cells (b) cultured in suspension at different cell concentrations. [Figure 10] FIG. 1 shows a schematic flow chart of the isolation and purification of engineered migrasomes derived from engineered NRK cells. [Figure 11] Morphological observation of engineered migrasomes induced in engineered NRK cells. a: Laser confocal microscope image of engineered migrasomes. b: Negative staining transmission electron microscope image of engineered migrasomes. c: Cryo-electron microscope image of engineered migrasomes. [Figure 12] FIG. 1 shows Western blotting of isolated and purified engineered migrasomes. [Figure 13] Figure 1 shows the permeability of engineered migrasomes to Cy5 and dextran-TMR over time as observed by laser confocal microscopy. a: Observation of engineered migrasomes by laser confocal microscopy. b: Statistical results of the percentage of engineered migrasomes permeable to dextran-TMR after storage at room temperature for 1.5, 6, 12, 24, and 48 hours. [Figure 14]Figure 2. Stability of engineered migrasomes. a: Morphological results of engineered migrasomes observed by laser confocal microscope on days 0, 1, 2, 3, 5, and 7. b: Western blotting analysis of chicken ovalbumin (OVA) and mCherry protein expression in purified engineered migrasomes after different days of storage at room temperature. c: OVA-specific antibodies produced after immunizing mice with engineered migrasomes stored at room temperature for different days. [Figure 15] FIG. 1 shows the effect of the cholesterol extraction reagent MβCD on the stability of engineered migrasomes as observed by laser confocal microscopy. [Figure 16] (a) Schematic of the loading of membrane proteins, soluble proteins and small molecules into engineered migrasomes (b) Schematic of the loading of soluble proteins by using OVA as an example. [Figure 17] FIG. 1 shows the positions of various membrane proteins loaded onto engineered migrasomes as observed by laser confocal microscopy. [Figure 18] FIG. 1 shows the location of spike proteins on engineered migrasomes as observed by laser confocal microscopy. [Figure 19] FIG. 1 shows a map of the vector pB-Hygro-GFP. [Figure 20] FIG. 1 shows a map of vector pmCherry-N1. [Figure 21] FIG. 1 shows a map of vector pB-Hygro-mCherry. [Figure 22] FIG. 1 shows the location of the fusion protein t-STX2-OVA on engineered migrasomes as observed by laser confocal microscopy. [Figure 23] FIG. 1 shows colocalization of Tspan4-HaloTag-GFP and HaloTag ligand-TMR on engineered migrasomes as observed by laser confocal microscopy. [Figure 24]Figure 1 shows the S protein-specific immune response induced in mice immunized with engineered migrasomes (e-migrasomes) expressing SARS-CoV-2 spike protein. a: Schematic diagram of animal experiment. b: Western blotting of S1 protein in spike-expressing e-migrasomes with control e-migrasome group and purified S1 protein as controls. c: Concentration of spike (S) protein-specific IgG in mouse serum after immunization with different methods. [Diagram 25] Characterization of migrasomes produced by engineered NRK cells. a: Scanning electron microscopy of hypotonically treated and 2.5% glutaraldehyde-fixed Tspan4-GFP-overexpressing NRK cells. Scale: 20 μm (left) and 2 μm (right). b: 4D images of engineered migrasomes produced by hypotonic treatment from Tspan4-GFP-overexpressing NRK cells using a spinning disk confocal microscope. During hypotonic treatment, it is observed that the cell body swells and the basal surface retracts to produce numerous filamentous structures, and engineered migrasomes grow on these filamentous structures. c: Electron micrograph of A-431 cells producing hypotonic vesicles, and a micrograph of the produced vesicles (References: Cohen S, Ushiro H, Stoscheck C, Chinkers MA native 170 000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J Biol Chem 257:1523-1531.). [Figure 26-1] Comparison of migrasomes and engineered migrasomes (e-migrasomes). a (left): Confocal microscopy of cultured untreated TSPAN4-mCherry-expressing NRK cells. Scale bar: 5 μm. b: Laser confocal microscopy of engineered migrasomes produced by Tspan4-GFP-expressing NRK cells via a hypotonic process. Scale bar: 5 μm. [Figure 26-2]Comparison of migrasomes with engineered migrasomes (e-migrasomes). c: Tetramethylrhodamine-labeled WGA-stained NRK cells overexpressing Tspan4-GFP. The top photo shows cells in isotonic solution, and the bottom photo shows cells after hypotonic treatment. These photos are Z-axis superimposed photos after scanning with a laser confocal microscope, and the scale is 5 μm. [Figure 26-3] Comparison of migrasomes with engineered migrasomes (e-migrasomes). d: Electron micrograph of migrasomes (Ma et al, Cell Res. 2015). e: Transmission electron microscopy image of engineered migrasomes produced by T4-GFP overexpressing NRK cells. Scale is 1 μm. f: Mass spectrometry comparison of e-migrasomes with control migrasomes. g: 25 proteins not detected in engineered migrasomes but highly enriched in control migrasomes. Numbers in the table represent Log2 (fold change in expression relative to the cell body). Experiments were repeated three times. [Figure 26-4]Comparison of migrasomes with engineered migrasomes (e-migrasomes).h: Engineered migrasomes showing enrichment of ERM family and various other proteins (lower panel) compared to control migrasomes (upper panel). The left three panels were acquired using Tspan-4-GFP imaging, Ezrin-mCherry imaging, and a merged Z-stack image of both, respectively, the second right panel is Fxyd5-mCherry imaging, and the first right panel is Atp1β1-mCherry imaging (references: Ma L, Li Y, Peng J, Wu D, Zhao X, Cui Y, Chen L, Yan X, Du Y, Yu L. Discovery of the migrasome, an organelle mediating release of cytoplasmic contents during cell migration. Cell Res. 2015 Jan;25(1):24-38. doi:10.1038 / cr.2014.135; Zhao X, Lei Y, Zheng J, Peng J, Li Y, Yu L, Chen Y. Identification of markers for migrasome detection. Cell Discov. 2019 May 21;5:27.doi:10.1038 / s41421-019-0093-y.Erratum in:Cell Discov.2022 Apr 6;8(1):32.PMID:31123599;PMCID:PMC6527679). [Figure 27-1] Comparison of small vesicles / exosomes and engineered migrasomes, both produced from Tspan4-GFP overexpressing MC-38 cells. a: Small vesicles / exosomes purification process. b: NTA examination of purified MC-38 small vesicles / exosomes. c: Examination of MC-38 small vesicles / exosomes by transmission electron microscopy (TEM). [Figure 27-2]Comparison of small vesicles / exosomes and engineered migrasomes, both produced from Tspan4-GFP-overexpressing MC-38 cells. d: Western blotting analysis of small vesicles / exosomes, engineered migrasomes, and cell bodies, all of the same cellular origin. [Figure 27-3] e: Comparison of small vesicles / exosomes and engineered migrasomes, both produced from Tspan4-GFP overexpressing MC-38 cells. f: In vivo distribution. Here, fluorescence imaging is performed on tissues taken at different times from small vesicles / exosomes or engineered migrasomes produced by MC-38 cells expressing Tspan4-GFP, subjected to DiD labeling and intravenously injected with equal fluorescent dye amounts. [Figure 28-1] Quantitative mass spectrometry of engineered migrasomes and small vesicles / exosomes, both of the same cellular origin. a: PCA analysis. b: Heatmap of signal pathway analysis. Note: The data points of the three sets of engineered migrasomes show high consistency and are overlapped in the figure. [Figure 28-2] Figure 1: Quantitative mass spectrometry of engineered migrasomes and small vesicles / exosomes, both of the same cellular origin. c: List of the 10 most enriched proteins of engineered migrasomes and small vesicles / exosomes produced. Note: The data points of the three sets of engineered migrasomes show high consistency, and the 10 most enriched proteins are in perfect agreement. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0121] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, the embodiments of the present invention will be described with reference to specific examples. Those skilled in the art will easily understand other advantages and effects of the present invention from the disclosure of the specification.

[0122] Terms and Definitions In this application, the term "relative movement" generally refers to movement that occurs relative to a reference point or surface. It refers to the movement of the cell center relative to the environment (e.g., the surface to which it is attached) or, in the case of a stationary cell center, the relative movement of the cell membrane surface relative to the surrounding microenvironment (e.g., the solid surface to which it is attached, or the liquid phase within the microenvironment) or relative to the cell center (e.g., swelling, rising from flat, etc.).

[0123] In this application, the term "migrasome" generally refers to a structure produced by a cell undergoing relative migration. For example, migrasomes can be a new type of organelle, e.g., a vesicular structure produced at the tip or intersection of retraction fibers that leave behind the cell during cell migration. For example, during cell migration, the cell body continuously transports intracellular materials to migrasomes, after which the retraction fibers are severed and the migrasomes are released locally or transported to distant tissues via body fluids such as blood, and then taken up by cells in or around the extracellular space. For example, migrasomes can be involved in the transmission of intracellular materials and intercellular signals, thereby mediating intercellular communication.

[0124] In this application, the term "membrane microdomain" generally refers to a region having a biological membrane structure. For example, sphingolipid and cholesterol (Ch)-based cell membrane microdomains include lipid rafts, tetraspanin-rich microdomains (TEMs), etc.

[0125] In this application, the term "intraluminal vesicle" generally refers to a membrane vesicle (e.g., a cell organelle or a larger vesicle) that is formed or present within a lumen or the space of a lumen or tubular structure. Lumen may also be used herein to refer to the interior space of a cell component or structure. For example, intraluminal vesicles may be produced by cell organelles. For example, intraluminal vesicles may include intraluminal vesicles in migrasomes, or intraluminal vesicles that are not currently in migrasomes but are expected to be transported into migrasomes.

[0126] In this application, the term "exogenous cargo" generally refers to a substance that is not naturally present in a chromosome or host cell. For example, the cell itself does not produce the substance or does not produce (e.g., express) the substance in comparable amounts. For example, cells that produce the substance are distinct from natural cells, such as in structure or function.

[0127] In this application, the term "hypotonic" generally refers to an osmotic pressure that is lower than the osmotic pressure of an isotonic solution of a cell. Isotonic solution refers to a solution that has an osmotic pressure equivalent to that of plasma.

[0128] In this application, the term "cytoskeleton" generally refers to the protein fiber network system within cells, eg, a system composed of microtubules, microfilaments, and intermediate filaments.

[0129] In this application, the term "tetraspanin" generally refers to the tetraspanin protein superfamily, which contains four transmembrane domains. These proteins can form so-called tetraspanin protein-rich microdomains (TEMs) (Rubinstein, E. (2011). The complexity of tetraspanins. Biochem Soc Trans 39, 501-505.). TEMs are about 100 nanometers in size and are rich in various proteins and lipid raft-like lipids, such as cholesterol. During migrasome formation, many small TEMs aggregate to form micron-scale macrodomains called tetraspanin-rich membrane macrodomains (TEMAs), the formation of which can be correlated with the growth of migrasomes on retraction fibers. For example, the tetraspanin family includes Tspan1, Tspan2, Tspan3, Tspan4, Tspan5, Tspan6, Tspan7, Tspan8, Tspan9, Tspan10, Tspan11, Tspan12, Tspan13, Tspan14, Tspan15, Tspan16, Tspan17, Tspan18, Tspan19, Tspan20 (UPK1B), Tspan It may contain 33 members, including n21 (UPK1A), Tspan22 (PRPH2), Tspan23 (ROM1), Tspan24 (CD151), Tspan25 (CD53), Tspan26 (CD37), Tspan27 (CD82), Tspan28 (CD81), Tspan29 (CD9), Tspan30 (CD63), Tspan31, Tspan32, and Tspan33. Data from biochemical studies and gene knockout mice suggest that these members of the tetraspanin family play important roles in membrane biology.

[0130] In this application, the terms "isolated" and "purified" are used interchangeably and generally refer to the identification, isolation, and / or recovery of migrasomes from components in the environment in which they are produced, such that these "isolated or purified" migrasomes are free or substantially free of other contaminant components from the environment that may interfere with the therapeutic or diagnostic use of these migrasomes. Contaminant components may include abiotic (including chemicals) or biological materials, such as organelles, nucleic acids, proteins (e.g., soluble proteins), lipids, or metabolic products. Thus, "isolated or purified" migrasomes may be produced by at least one purification step that removes or substantially removes these contaminant components.

[0131] In this application, the term "and / or" should be understood to mean either or both of the optional items.

[0132] In this application, the term "comprising" generally refers to the inclusion of explicitly specified features but not to the exclusion of other elements.

[0133] In this application, the term "about" generally refers to a variation within a range of 0.5% to 10% above or below the specified value, for example, variations within ranges of 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, and 10% above or below the specified value.

[0134] Detailed Description of the Invention In one aspect, the present application provides a method for producing migrasomes. The method may include relative movement of cells to produce migrasomes derived from the cells. For example, relative movement in the present application may refer to the movement of the cell center relative to the environment (e.g., the surface to which it is attached), or in the case of a stationary cell center, the relative movement of the cell membrane surface relative to the surrounding microenvironment (e.g., the solid surface to which it is attached, or the liquid phase within the microenvironment) or relative to the cell center (e.g., swelling, rising from flat, etc.). For example, the occurrence and / or extent of relative movement may be mediated by physical and / or chemical and / or biological means.

[0135] In a method according to one embodiment, the method may further comprise isolating migrasomes produced by the cells.

[0136] For example, the methods of the present application may include subjecting the cells to hypotonic treatment, disrupting the cytoskeleton of the cells, inhibiting the cell volume regulatory function of the cells, detaching the cells from the surface to which they are attached, and / or causing relative movement between the plasma membrane of the cells and the surface to which they are attached, and may include increasing the number and / or function of tetraspanin proteins, functional fragments thereof, and / or functional variants thereof in the cells.

[0137] For example, the method of the present application may include disrupting the cytoskeleton of the cell, inhibiting the cell volume regulatory function of the cell, detaching the cell from the adherent surface, and / or moving the cell between the cell membrane and the adherent surface relative to each other, and may include increasing the number and / or function of tetraspanin proteins, functional fragments, and / or functional variants thereof in the cell. For example, the method of the present application may include subjecting the cell to a hypotonic treatment, inhibiting the cell volume regulatory function of the cell, detaching the cell from the adherent surface, and / or moving the cell between the cell membrane and the adherent surface relative to each other, and may include increasing the number and / or function of tetraspanin proteins, functional fragments, and / or functional variants thereof in the cell. For example, the method of the present application may include subjecting the cell to a hypotonic treatment, disrupting the cytoskeleton of the cell, detaching the cell from the adherent surface, and / or moving the cell between the cell membrane and the adherent surface relative to each other, and may include increasing the number and / or function of tetraspanin proteins, functional fragments, and / or functional variants thereof in the cell. For example, the methods of the present application may include subjecting the cells to a hypotonic treatment, disrupting the cytoskeleton of the cells, inhibiting a cell volume regulatory function of the cells, and / or causing a relative movement between the cell membrane and the adherent surface of the cells, and may include increasing the number and / or function of tetraspanin proteins, functional fragments, and / or functional variants thereof in the cells. For example, the methods of the present application may include subjecting the cells to a hypotonic treatment, disrupting the cytoskeleton of the cells, inhibiting a cell volume regulatory function of the cells, and / or detaching the cells from the adherent surface, and may include increasing the number and / or function of tetraspanin proteins, functional fragments, and / or functional variants thereof in the cells.

[0138] For example, the method of the present application may include suppressing the cell volume regulatory function of the cell, detaching the cell from the adherent surface, and / or moving the cell between the cell membrane and the adherent surface relative to each other, and may include increasing the number and / or function of tetraspanin proteins, functional fragments, and / or functional variants thereof in the cell. For example, the method of the present application may include subjecting the cell to a hypotonic treatment, detaching the cell from the adherent surface, and / or moving the cell between the cell membrane and the adherent surface relative to each other, and may include increasing the number and / or function of tetraspanin proteins, functional fragments, and / or functional variants thereof in the cell. For example, the method of the present application may include subjecting the cell to a hypotonic treatment, disrupting the cytoskeleton of the cell, and / or suppressing the cell volume regulatory function of the cell, and may include increasing the number and / or function of tetraspanin proteins, functional fragments, and / or functional variants thereof in the cell.

[0139] For example, the method of the present application may include subjecting the cell to a hypotonic treatment and / or a relative movement between the cell membrane and the adherent surface of the cell, and may include increasing the number and / or function of tetraspanin proteins, functional fragments, and / or functional variants thereof in the cell. For example, the method of the present application may include disrupting the cytoskeleton of the cell and / or a relative movement between the cell membrane and the adherent surface of the cell, and may include increasing the number and / or function of tetraspanin proteins, functional fragments, and / or functional variants thereof in the cell. For example, the method of the present application may include inhibiting the cell volume regulatory function of the cell and / or a relative movement between the cell membrane and the adherent surface of the cell, and may include increasing the number and / or function of tetraspanin proteins, functional fragments, and / or functional variants thereof in the cell.

[0140] For example, in the methods of the present application, the methods may include subjecting the cells to a hypotonic treatment.

[0141] For example, in the methods of the present application, the hypotonic treatment may include placing the cells in a hypotonic buffer.

[0142] For example, in the methods of the present application, hypotonic treatment may include placing cells in a buffer and reducing the osmolarity of the buffer to make it a hypotonic buffer.

[0143] For example, in the methods of the present application, the decrease may include a linear decrease and / or a stepwise decrease.

[0144] For example, in the methods of the present application, the osmolality of the hypotonic buffer may be less than about 305 mOsmol / L. For example, the osmolality of the hypotonic buffer may be less than about 305 mOsmol / L, less than about 300 mOsmol / L, less than about 270 mOsmol / L, less than about 250 mOsmol / L, less than about 200 mOsmol / L, less than about 150 mOsmol / L, less than about 100 mOsmol / L, less than about 90 mOsmol / L, less than about 80 mOsmol / L, less than about 70 mOsmol / L, less than about 60 mOsmol / L, less than about 50 mOsmol / L, less than about 40 mOsmol / L, less than about 30 mOsmol / L, less than about 20 mOsmol / L, less than about 15 mOsmol / L, less than about 10 mOsmol / L, less than about 5 mOsmol / L, or less than about 2 mOsmol / L.

[0145] For example, in the method of the present application, the osmotic pressure of the hypotonic buffer solution may be about 10 mOsmol / L to about 274.5 mOsmol / L. For example, in the method of the present application, the osmotic pressure of the hypotonic buffer solution may be about 10 mOsmol / L to about 274.5 mOsmol / L. For example, the osmotic pressure of the hypotonic buffer solution is about 10 mOsmol / L to about 300 mOsmol / L, about 20 mOsmol / L to about 300 mOsmol / L, about 30 mOsmol / L to about 300 mOsmol / L, about 50 mOsmol / L to about 300 mOsmol / L, about 70 mOsmol / L to about 300 mOsmol / L, about 100 mOsmol / L to about 300 mOsmol / L, about 150 mOsmol / L to about 300 mOsmol / L, about 200 mOsmol / L to about 300 mOsmol / L, Approx. 250mOsmol / L~Approx. 300mOsmol / L, Approx. 10mOsmol / L~Approx. 250mOsmol / L, Approx. 20mOsmol / L~Approx. 250mOsmol / L, Approx. 30mOsmol / L~Approx. 250mOsmol / L, Approx. 50mOsmo l / L~about 250mOsmol / L, about 70mOsmol / L~about 250mOsmol / L, about 100mOsmol / L~about 250mOsmol / L, about 150mOsmol / L~about 250mOsmol / L, about 200mOsmol / L~about 25 0mOsmol / L, about 10mOsmol / L to about 200mOsmol / L, about 20mOsmol / L to about 200mOsmol / L, about 30mOsmol / L to about 200mOsmol / L, about 50mOsmol / L to about 200mOsmol / L , about 70mOsmol / L to about 200mOsmol / L, about 100mOsmol / L to about 200mOsmol / L, about 150mOsmol / L to about 200mOsmol / L, about 10mOsmol / L to about 150mOsmol / L, about 20mOsm ol / L~about 150mOsmol / L, about 30mOsmol / L~about 150mOsmol / L, about 50mOsmol / L~about 150mOsmol / L, about 70mOsmol / L~about 150mOsmol / L, about 100mOsmol / L~about 15 0mOsmol / L, about 10mOsmol / L to about 100mOsmol / L, about 20mOsmol / L to about 100mOsmol / L, about 30mOsmol / L to about 100mOsmol / L, about 50mOsmol / L to about 100mOsmol / L,The hypotonicity may be about 70 mOsmol / L to about 100 mOsmol / L, about 10 mOsmol / L to about 30 mOsmol / L, about 20 mOsmol / L to about 30 mOsmol / L, about 30 mOsmol / L to about 90 mOsmol / L, or about 30 mOsmol / L to about 70 mOsmol / L. Hypotonic treatment involves placing the cells in a buffer and reducing the osmotic pressure of the buffer to make it a hypotonic buffer.

[0146] For example, in the methods of the present application, the methods may include disrupting the cytoskeleton of a cell.

[0147] For example, in the method of the present application, disrupting the cytoskeleton of the cell may include contacting the cell with a cytoskeleton disrupting reagent. For example, in the method of the present application, the cytoskeleton disrupting reagent may include a microfilament and / or microtubule depolymerizing agent. For example, in the method of the present application, the cytoskeleton disrupting reagent may include latrunculin A, latrunculin B, cytochalasin A, cytochalasin B, cytochalasin C, cytochalasin D, and / or cytochalasin E.

[0148] For example, in the methods of the present application, the methods may include inhibiting a cell volume regulatory function of a cell.

[0149] For example, in the methods of the present application, inhibiting a cell volume regulatory function of a cell may include reducing the number and / or function of volume regulatory proteins in the cell. For example, with respect to an unmodified cell, inhibiting a cell volume regulatory function of a cell in the present application reduces the number and / or function of volume regulatory proteins in the cell by about 5%, about 10%, about 20%, about 50%, or about 100%.

[0150] For example, in the method of the present application, the volume-regulating protein may comprise a volume-regulating ion channel and / or a transporter. For example, in the method of the present application, the volume-regulating ion channel may comprise a volume-regulating anion channel VRAC and / or a volume-regulating cation channel VRCC. For example, in the method of the present application, the volume-regulating anion channel VRAC may comprise SWELL1 or a functionally active fragment thereof. For example, in the method of the present application, the volume-regulating cation channel VRCC may comprise TRPV4, TRPM3, and / or a functionally active fragment thereof.

[0151] For example, in the methods of the present application, the transporter may include a cotransporter. For example, in the methods of the present application, the cotransporter may include KCC1, KCC3, and / or KCC4.

[0152] For example, in the methods of the present application, inhibiting the cell volume regulatory function of the cells may include placing the cells in a buffer that can inhibit the volume regulatory ability of the cells. For example, in the methods of the present application, the buffer may include increased cations. For example, in the methods of the present application, the cations may include K + , Na + , Cs + , Li + , Ca 2+ , Mg 2+ , B.A. 2+ , Mn 2+ , Fe 2+ , Ni 2+ , Zn 2+ , Al 3+ , Fe 3+ , CH3NH3 + , C2H5NH3 + , (CH3)2NH2 + , (C2H5)2NH2 + , (C2H5)3N + , ammonium ions, and / or choline ions.

[0153] For example, in the methods of the present application, the buffer may contain increased anions. For example, in the methods of the present application, the anions may be Br- , Cl - , I - , F - , O.H. - , HCO3 - , H2PO4 - , NO2 - , NO3 - , C.N. - , HPO4 2- , CO3 2- , SO4 2- , and / or PO4 3- may include:

[0154] For example, in the methods of the present application, the methods may include detaching the cells from the surface to which they are attached.

[0155] For example, in the methods of the present application, the methods may include causing a relative movement between the cell membrane of the cell and the adherent surface.

[0156] For example, in the methods of the present application, the methods may further comprise increasing the number and / or function of tetraspanin proteins, functional fragments thereof, and / or functional variants thereof in the cell. For example, in the methods of the present application, the methods may comprise overexpressing tetraspanin proteins, functional fragments thereof, and / or functional variants thereof in the cell. For example, in the methods of the present application, the tetraspanin proteins are Tspan1, Tspan2, Tspan3, Tspan4, Tspan5, Tspan6, Tspan7, Tspan8, Tspan9, Tspan10, Tspan11, Tspan12, Tspan13, Tspan14, Tspan15, Tspan16, Tspan17, Tspan18, Tspan19, Tspan20 (UPK1 B), Tspan21 (UPK1A), Tspan22 (PRPH2), Tspan23 (ROM1), Tspan24 (CD151), Tspan25 (CD53), Tspan26 (CD37), Tspan27 (CD82), Tspan28 (CD81), Tspan29 (CD9), Tspan30 (CD63), Tspan31, Tspan32, and Tspan33.

[0157] For example, in the methods of the present application, the methods may further comprise reducing the size of the migrasomes.

[0158] For example, in the methods of the present application, reducing the size of the migrasomes may include extruding the migrasomes in a filter or extruder.

[0159] For example, in the method of the present application, the filter or extruder may have a pore size of about 30 nm to about 10,000 nm. For example, the filter or extruder may have a pore size of about 30 nm to about 100 nm, about 30 nm to about 1000 nm, about 30 nm to about 10,000 nm, about 50 nm to about 100 nm, about 50 nm to about 1000 nm, about 50 nm to about 10,000 nm, about 100 nm to about 1000 nm, about 100 nm to about 10,000 nm, or about 1000 nm to about 10,000 nm.

[0160] For example, in the method of the present application, migrasomes may have a size of about 50 nm to about 8000 nm. For example, migrasomes may have a size of about 50 nm to about 100 nm, about 50 nm to about 1000 nm, about 50 nm to about 10000 nm, about 100 nm to about 10000 nm, about 100 nm to about 10000 nm, or about 1000 nm to about 10000 nm.

[0161] For example, in the methods of the present application, migrasomes may be generated from retraction fibers of cells.

[0162] For example, in the method of the present application, the membrane of the migrasome may be enriched with sodium / potassium ATPase and / or functional fragments thereof. For example, in the method of the present application, the membrane of the migrasome may be enriched with integrins and / or functional fragments thereof. For example, in the method of the present application, the membrane of the migrasome may be enriched with tetraspanin proteins, functional variants thereof, and / or functional fragments thereof. For example, in the method of the present application, the membrane of the migrasome may be enriched with cholesterol. For example, enrichment may refer to a state when compared to other portions on the cell membrane of the corresponding cell, or when compared to the state of the corresponding cell membrane before the production of the migrasome. For example, enrichment refers to the fact that the density of a molecule or substance on the migrasome of the present application is higher than the density of the corresponding molecule or substance on the cell membrane that produces the migrasome.

[0163] For example, in the method of the present application, migrasomes may be enriched in membrane microdomains. For example, membrane microdomains refer to sphingolipid and cholesterol (Ch)-based cell membrane microdomains, including lipid rafts, tetraspanin-rich microdomains (TEMs), and the like.

[0164] For example, in the methods of the present application, migrasomes may be produced in vitro or ex vivo.

[0165] For example, in the methods of the present application, the contents of migrasomes may be at least partially reduced or absent compared to natural migrasomes produced by the same cells. For example, in the case of engineered migrasomes produced by NRK cells, more than 4000 proteins are absent in migrasomes compared to natural migrasomes, which have about 1350 proteins (i.e., extra proteins) not found in natural migrasomes, such as AMP3, Myh4, Gorasp2, Asz1, Lats2, Scn2b, Pacsin1, and Alb. For example, "natural migrasomes" may refer to migrasomes produced by cells that spontaneously migrate without altering external culture conditions (e.g., hypotonicity, temperature, etc.), while "engineered migrasomes" may refer to migrasomes produced by cells that have undergone relative migration induced by external stimuli.

[0166] For example, in the methods of the present application, the at least partially reduced contents may include intraluminal vesicles. For example, engineered migrasomes provided by the present application have fewer internal intraluminal vesicles. Intraluminal vesicles may refer to vesicles that have a phospholipid bilayer structure in the outer membrane structure.

[0167] For example, in the methods of the present application, the methods may be in vitro methods or ex vivo methods. For example, the methods of production in the present application may be performed in vitro. For example, the methods of production in the present application may not be performed in vivo.

[0168] For example, in the methods of the present application, the cells may be cells cultured in vitro.

[0169] For example, in the methods of the present application, the cells may be suspension cultured cells or adherent cultured cells.

[0170] For example, in the methods of the present application, the cells may include primary cells.

[0171] For example, in the methods of the present application, primary cells may include tissue cells derived from organisms that may include humans, monkeys, mice, rats, rabbits, chickens, and / or insects.

[0172] For example, in the methods of the present application, the primary cells may include liver cells, spleen cells, kidney cells, tissue macrophages, brain glial cells, osteoclasts, bone marrow cells, leukocytes, fibroblasts, and / or adipocytes. For example, the primary cells in the present application may include Kupffer cells, a type of phagocyte that is located on the inner surface of the liver sinusoids and can capture substances such as foreign antigens, antigen-antibody complexes, and cell debris from the blood.

[0173] For example, in the methods of the present application, leukocytes may include B cells, T cells, NK cells, dendritic cells, neutrophils, and / or macrophages.

[0174] For example, in the methods of the present application, the cells may include tumor cells.

[0175] For example, in the methods of the present application, tumor cells may include tumor cell lines, primary or limited passage tumor cells derived from a patient, tumor stromal cells, and / or tumor organoids.

[0176] For example, in the methods of the present application, the cells may include CHO cells, CHO-K1 cells, HEK293 cells, HEK293T cells, HEK293FT cells, HEK293F cells, Vero cells, NRK cells, L929 cells, MC38 cells, 4T1 cells, DC2.4 cells, MGC803 cells, Jurkat cells, NK-92MI cells, BJ cells, and / or HepG2 cells.

[0177] For example, in the methods of the present application, the cells may include white blood cells, stem cells, and / or fibroblasts.

[0178] For example, in the methods of the present application, the stem cells may include mesenchymal stem cells.

[0179] For example, the present application provides migrasomes produced by the method of the present application. For example, the present application provides new extracellular vesicles that can be produced by engineering approaches, i.e., engineered migrasomes, and / or migrasomes that are forcibly produced by cells with high efficiency by engineering approaches, and / or compositions that include any one of the above migrasomes. Engineered migrasomes have a size of 50-8000 nanometers (nm) and have membranes that are enriched with proteins such as integrins and tetraspanin (Tspan) family members. In some cases, engineered migrasomes grow on thread-like structures around the cells due to the presence of membrane microdomains, but can be spontaneously released from the cells or artificially isolated to obtain complete vesicle-like structures, and / or the biochemical composition, morphology, and structure of the engineered migrasomes are similar to those of natural migrasomes produced by the same cells. Engineered migrasomes may also be specifically tailored according to application needs to obtain vesicle-like structures that are significantly different from the natural migrasomes of the cells in terms of structure and biochemical composition. For example, the present application provides the use of migrasomes / engineered migrasomes as drug-loaded delivery vectors in the fields of therapy and vaccines for various diseases (e.g., tumors, inflammatory / autoimmune diseases, cardiovascular diseases, neurodegenerative diseases, and other neurological diseases, etc.).

[0180] Migrasomes are newly discovered organelles, unilamellar vesicular structures with diameters of 0.5-3 μm, produced at the tips or intersections of retraction fibers that leave behind cells during cell migration. For example, during cell migration, the cell body continuously transports intracellular materials into migrasomes. The retraction fibers are then cleaved, and migrasomes can be released locally or transported to distant tissues via body fluids such as blood, and then taken up by cells in or around the extracellular space. This suggests that migrasomes may participate in the transmission of intracellular materials and intercellular signals, thereby mediating intercellular communication (Liang Ma et.al.,Discovery of the migrasome,an organelle mediating release of cytoplasmic contents during cell migration,Cell Res(2015)25:24-38).

[0181] Studies have shown that migrasomes play important signaling roles in embryonic development, immune response, tumors, angiogenesis, tissue regeneration, and other processes involving active cell migration. Studies on migrasomes in zebrafish embryonic development have found that migrasomes function as membrane-coated vectors of signal molecules to determine the spatiotemporal distribution of signal molecules, thereby regulating organ development (Jiang D et.at.,Migrasomes provide regional cues for organ morphogenesis during zebrafish gastrulation,Nat Cell Biol,2019,21(8):966-977). Migrasomes can mediate the intercellular movement of proteins and mRNA, which are transferred to recipient cells via migrasomes, thereby changing the vital activities of the recipient cells (Zhu M et.al., Lateral transfer of mRNA and protein by migrasomes modifies the recipient cells, Cell Res, 2020, doi;10.1038 / s41422-020-00415-3). Migrasomes can regulate mitochondrial quality by removing damaged mitochondria, thereby maintaining mitochondrial homeostasis in cells (Jiang H et.al., Mitocytosis, a migrasome-mediated mitochondrial quality control process, Cell Press, doi:10.1016 / j.cell.2021.04.027). Migrasomes have a regulatory effect on cancer cells in the tumor microenvironment.For example, in pancreatic cancer cells, migrasomes can induce an inhibitory immune microenvironment to promote tumor growth (Zhang RH, A study of inter-regulatory effects of migrasomes in pancreatic cancer cells on phenotype and function of cancer cells and related immune cells in tumor microenvironment, 2020).

[0182] Exfoliated migrasomes are a type of extracellular vesicle that exhibit many differences from known extracellular vesicles. For example, the differences between detached migrasomes and exosomes are: 1) different structure: migrasomes exhibit a structure with small vesicles that bind to retraction fibers and are contained in large vesicles before being released, while exosomes do not; 2) different size: exosomes have a diameter of about 50-150 nm, while migrasomes have a diameter of about 0.5-3 μm; 3) distinctly different protein composition: migrasomes and exosomes share only 27% of their protein composition, for example, NDST1 (bifunctional heparan sulfate N-deacetylase / N-sulfotransferase 1), PIGK (phosphatidylinositol glycan anchor biosynthesis class K), CPQ (carboxypeptidase Q), and EOGT (EGF domain-specific O-linked N-acetylglucosamine transferase) are enriched on migrasomes but not present in exosomes (Zhao X, Lei Y, Zheng J, Peng J, Li Y,Yu L,Chen Y.Identification of markers for migrasome detection.Cell Discov.2019 May 21;5:27); and 4) completely different biogenesis processes resulting from regulation by different genetic pathways: exosomes are initially produced as vesicles in multivesicular bodies (MVBs) and are released upon fusion of the MVBs to the plasma membrane, whereas migrasomes are formed by the assembly of large domains on the plasma membrane (Huang Y,Zucker B,Zhang S,Elias S,Zhu Y,Chen H,Ding T,Li Y,Sun Y,Lou J,Kozlov MM*,Yu L*.Migrasome formation is mediated by assembly of micron-scale tetraspanin macrodomains.Nat Cell Biol.2019 Aug;21(8):991-1002).

[0183] In the present application, it has been found that various methods can induce the production of engineered migrasomes that are similar in structure to natural migrasomes. These engineered migrasomes are different from the "hypotonicity-induced vesicles" known in the art (e.g., vesicles as shown in Figure 1, Cohen S, Ushiro H, Stoscheck C, Chinkers MA native 170 000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J Biol Chem 257:1523-1531). They have at least the following differences: 1) different vesicle production sites: engineered migrasomes are produced on the retraction fibers around the cell, whereas vesicles are produced on the top surface of the cell according to Cohen et al.; 2) different vesicle size: engineered migrasomes have a micron-level size and a diameter rarely exceeding 5 μm, whereas vesicles induced by Cohen et al. using hypoosmotic pressure can be as large as 20 μm; and 3) unlike the method of hypotonic induction according to Cohen et al., hypotonicity may not be required for the production of engineered migrasomes in the present application and can be induced by other methods.

[0184] At present, engineered extracellular vesicles have been widely applied in important biomedical fields, such as drug delivery and vaccine production. For example, engineered exosomes (Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, Lee JJ, Kalluri R. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017 Jun 22;546(7659):498-503. doi:10.1038 / nature22341) have the following main advantages: natural biomembrane source and low toxicity; low immunogenicity, which makes them less likely to be eliminated by the immune system and allows for a long internal circulation time; and property stability, which allows for long-term storage at -80°C. However, they also exhibit obvious limitations, such as low yields; dependence on ultracentrifuge during purification; the main content is nucleic acid loaded after purification; etc.

[0185] In the present application, engineered migrasomes are of biological origin and have been found to share the advantages of low toxicity and low immunogenicity with extracellular vesicles of biological origin such as exosomes. Engineered migrasomes are newly discovered extracellular vesicles with unique characteristics in cargo type and in vivo biodistribution, and at the same time, the method for producing engineered migrasomes is high-yield and simple. In summary, the engineered migrasomes discovered by the present application have great potential in the biomedical field, such as drug delivery and vaccine production.

[0186] Methods for producing engineered migrasomes include artificially inducing cells to produce engineered migrasomes and isolating and / or purifying the engineered migrasomes and / or forcing relative movement between the cell membrane and the culture environment, including the solid surface to which it is attached and the surrounding liquid environment. Movement includes, but is not limited to, natural cell movement patterns or relative movement of the cell membrane with respect to the environment on a subcellular scale.

[0187] In another aspect, the present application provides migrasomes produced in vitro or ex vivo. The migrasomes may have a size of about 50 nm to about 8000 nm.

[0188] For example, in the migrasomes of the present application, migrasomes may be produced in vitro from retraction fibers of cells.

[0189] For example, in the migrasomes of the present application, the membrane of the migrasome may be enriched with sodium / potassium ATPase and / or functional fragments thereof.

[0190] For example, in the migrasomes of the present application, the membrane of the migrasome may be enriched with integrins and / or functional fragments thereof.

[0191] For example, in the migrasomes of the present application, the membrane of the migrasome may be enriched with tetraspanin proteins, functional variants thereof, and / or functional fragments thereof.

[0192] For example, in the migrasomes of the present application, the membrane of the migrasome may be enriched with cholesterol.

[0193] For example, in the migrasomes of the present application, the migrasomes may be enriched in membrane microdomains.

[0194] For example, in the migrasomes of the present application, the migrasome content may be at least partially reduced or absent as compared to native migrasomes produced by the corresponding cells.

[0195] For example, in the migrasomes of the present application, the at least partially reduced contents may include intraluminal vesicles.

[0196] In another aspect, the present application provides the use of migrasomes in the delivery of exogenous cargo. For example, "exogenous cargo" may refer to a substance that is not produced or not produced (e.g., expressed) in equal amounts by the cell itself, or a substance that is structurally or functionally different from the substance produced by the cell itself, such as the substances described above, even if the substance is produced by the cell itself as exogenous cargo.

[0197] For example, as used herein, migrasomes may include the migrasomes of the present application.

[0198] In another aspect, the present application provides a delivery system that may include migrasomes and one or more exogenous cargoes.

[0199] For example, in the delivery system of the present application, the exogenous cargo may be directly or indirectly incorporated, conjugated, or intercalated into the membrane and / or interior of the migrasome.

[0200] For example, in the delivery system of the present application, the migrasomes may comprise the migrasomes of the present application.

[0201] For example, in the delivery system of the present application, the migrasomes may be derived from cells.

[0202] For example, in the delivery system of the present application, the exogenous cargo may include one or more targeting agents and / or therapeutically active agents.

[0203] For example, in the delivery system of the present application, the exogenous cargo may comprise a protein, a lipid, a polynucleotide, a small molecule compound, a complex, a polysaccharide, a polymer, a nanoparticle, a microparticle, and / or an organelle.

[0204] For example, in the delivery system of the present application, the exogenous cargo may comprise a membrane protein, a soluble protein, and / or a polypeptide.

[0205] For example, in the delivery system of the present application, the exogenous cargo may comprise DNA and / or RNA.

[0206] For example, in the delivery system of the present application, the exogenous cargo may include an antibody or an antigen-binding antibody fragment thereof, an integrin or a fragment thereof, an immunogenic protein, a cytokine, a chemokine, a receptor protein or a fragment thereof, an enzyme, a tumor suppressor gene product, an siRNA, a microRNA, an antisense oligonucleotide (ASO), an mRNA, a DNA, a gene editing tool, and / or a cytotoxic agent. For example, the gene editing tool may include a nuclease, such as a Cas protein, a CRISPR-Cas system, a Cre recombinase, a zinc finger endonuclease, a transcription activator-like effector nuclease, and a gene epigenetic editing tool.

[0207] For example, in the delivery system of the present application, the exogenous cargo may include PAMPs, DAMPs, CD47, CD24, IL-12, IL-15, coagulation factor VII, coagulation factor VIII, coagulation factor IX, and / or functionally active fragments thereof.

[0208] For example, in the delivery system of the present application, exogenous cargo may be directly or indirectly incorporated into migrasomes by gene editing, exogenous expression, liquid-solid conversion, membrane fusion, charge adsorption, physical adsorption, and / or chemical conjugation. For example, exogenous expression may include, for example, plasmid expression, for example, to establish cell lines with transient or stable overexpression of genes.

[0209] For example, in the delivery system of the present application, exogenous cargo may be incorporated or intercalated into migrasomes by direct or indirect conjugation to membrane components of the migrasome.

[0210] For example, in the delivery system of the present application, the membrane components of the migrasomes may include membrane proteins, cholesterol, phospholipids, carbohydrate chains on glycoproteins, and / or polysaccharides.

[0211] For example, in the delivery system of the present application, indirect conjugation may include binding via click chemistry.

[0212] For example, in the delivery system of the present application, indirect conjugation may include providing an exogenous cargo conjugated to a first member of a binding pair and contacting the exogenous cargo with a migrasome, where the membrane of the migrasome includes a second member of the binding pair and the first member is capable of binding to the second member.

[0213] For example, in the delivery system of the present application, the first and second members of the binding pair may be selected from an antigen and its antibody; a receptor and its ligand; biotin and avidin; HaloTag and its ligand; and CP05 and CD63.

[0214] For example, in the delivery system of the present application, the exogenous cargo may be expressed on the inner or outer surface of the membrane of the migrasome as a membrane protein. For example, in the delivery system of the present application, the exogenous cargo may be expressed on the inner or outer surface of the membrane of the migrasome as a fusion protein fused to a membrane protein or a portion thereof.

[0215] For example, in the delivery system of the present application, the exogenous cargo may be expressed on the inner or outer surface of the migrasome membrane as a fusion protein fused to a membrane protein or portion thereof by gene editing and / or exogenous expression.

[0216] In another aspect, the present application provides a method of making a delivery system. The method may include providing a migrasome and allowing the migrasome to carry an exogenous cargo. For example, the exogenous cargo carried by the migrasome may include a reversibly bound exogenous cargo. For example, the exogenous cargo carried by the migrasome may include an irreversibly conjugated exogenous cargo.

[0217] For example, in the methods of the present application, migrasomes may be isolated or purified migrasomes.

[0218] For example, in the methods of the present application, loading a migrasome with an exogenous cargo may include directly or indirectly incorporating or intercalating the exogenous cargo into the membrane and / or interior of the migrasome.

[0219] For example, in the methods of the present application, the methods may further comprise isolating or purifying migrasomes from the cells.

[0220] For example, in the methods of the present application, the methods may include providing a complex of an exogenous cargo and a first member of a binding pair, causing a cell to produce a migrasome, which may include a second member of the binding pair, and contacting the migrasome with the complex to form a delivery system.

[0221] For example, in the methods of the present application, the migrasomes may include the migrasomes of the present application.

[0222] For example, in the methods of the present application, migrasomes may be derived from cells.

[0223] For example, in the methods of the present application, the exogenous cargo may include one or more targeting agents and / or therapeutically active agents.

[0224] For example, in the methods of the present application, the exogenous cargo may comprise a protein, a lipid, a polynucleotide, a small molecule compound, a complex, a polysaccharide, a polymer, a nanoparticle, a microparticle, and / or an organelle.

[0225] For example, in the methods of the present application, the exogenous cargo may comprise a membrane protein, a soluble protein, and / or a polypeptide.

[0226] For example, in the methods of the present application, the exogenous cargo may comprise DNA and / or RNA.

[0227] For example, in the methods of the present application, the exogenous cargo may comprise an antibody or an antigen-binding antibody fragment thereof, an integrin or a fragment thereof, an immunogenic protein, a cytokine, a chemokine, a receptor protein or a fragment thereof, an enzyme, a tumor suppressor gene product, an siRNA, a microRNA, an antisense oligonucleotide (ASO), an mRNA, DNA, a gene editing tool, and / or a cytotoxic agent.

[0228] For example, in the methods of the present application, the exogenous cargo may include PAMPs, DAMPs, CD47, CD24, IL-12, IL-15, coagulation factor VII, coagulation factor VIII, coagulation factor IX, and / or functionally active fragments thereof.

[0229] For example, in the methods of the present application, exogenous cargo may be incorporated into migrasomes directly or indirectly by gene editing, exogenous expression, liquid-solid conversion, membrane fusion, charge adsorption, physical adsorption, and / or chemical conjugation.

[0230] For example, in the methods of the present application, exogenous cargo may be incorporated into or intercalated into migrasomes by direct or indirect conjugation to membrane components of the migrasome.

[0231] For example, in the methods of the present application, the membrane components of the migrasome may include membrane proteins, cholesterol, phospholipids, carbohydrate chains on glycoproteins, and / or polysaccharides.

[0232] For example, in the methods of the present application, indirect conjugation may include binding via click chemistry.

[0233] For example, in the methods of the present application, indirect conjugation may include providing an exogenous cargo conjugated to a first member of a binding pair and contacting the exogenous cargo with a migrasome, where the membrane of the migrasome includes a second member of the binding pair and the first member is capable of binding to the second member.

[0234] For example, in the methods of the present application, the first and second members of the binding pair may be selected from an antigen and its antibody; a receptor and its ligand; biotin and avidin; HaloTag and its ligand; and CP05 and CD63.

[0235] For example, in the methods of the present application, the exogenous cargo may be expressed as a membrane protein on the inner or outer surface of the membrane of the migrasome.

[0236] For example, in the methods of the present application, the exogenous cargo may be expressed on the inner or outer membrane of the migrasome as a fusion protein fused to a membrane protein or portion thereof.

[0237] In another aspect, the present application provides a method of making a delivery system, which may include expressing an mRNA in a cell, causing the cell to produce a migrasome, which may include an mRNA binding protein, and binding the mRNA to the migrasome via the mRNA binding protein. For example, the mRNA binding protein may include a protein-formed complex for binding to the mRNA. For example, the RNA binding protein includes an RNA recognition motif. The RNA binding protein has native or inactivated nuclease activity. The RNA binding protein or functional domain thereof may include Cys2-His2, Gag-knuckle, Trebleclet, zinc ribbon, Zn2 / Cys6-like motifs. Exemplary mRNA binding proteins may include, but are not limited to, RNA binding proteins (RBPs).

[0238] In another aspect, the present application provides a method of making a delivery system, which may include causing a cell to express an exogenous cargo on the cell membrane and causing the cell to produce a migrasome that may include the exogenous cargo. Expressing the exogenous cargo may be performed by gene editing or exogenous expression, such as plasmid expression.

[0239] For example, in the methods of the present application, the exogenous cargo may be a protein.

[0240] For example, in the methods of the present application, the protein may be a membrane protein.

[0241] For example, in the methods of the present application, the protein may be a soluble protein or may be fused to a membrane protein or portion thereof to form a fusion protein.

[0242] In another aspect, the present application provides compositions that may include the migrasomes of the present application or the delivery systems of the present application.

[0243] 1. A method for producing engineered migrasomes, comprising: (a) treating the cells with one or more of the following to induce the cells to produce engineered migrasomes: (1) Hypotonic treatment, (2) disrupting the cell's cytoskeleton; (3) inhibiting the cell volume regulation function of cells; and (4) overexpressing in the cell one or more proteins selected from members of the tetraspanin family; and (5) Inducing cells to rapidly detach from the surface to which they are attached or inducing the cell membrane to move relative to the surface to which they are attached. (b) isolating and / or purifying the engineered migrasomes. The method includes:

[0244] 2. The method according to technical solution 1, wherein in step (a), at least one process among (2) to (5) is performed, or at least two processes, at least three processes, at least four processes, or all five processes among (1) to (5) are performed.

[0245] 3. The method according to technical solution 1 or 2, wherein step (a) comprises subjecting the cells to a hypotonic treatment.

[0246] 4. The method according to any one of technical solutions 1 to 3, wherein the hypotonic treatment is carried out by placing the cells in a hypotonic buffer solution having an osmolality of 30.5 to 274.5 mOsmol / L, for example 30.5 to 150 mOsmol / L.

[0247] 5. The method according to any one of technical solutions 1 to 3, wherein the hypotonic treatment is carried out by placing the cells in a buffer and reducing the osmolarity of the buffer to 30.5 to 274.5 mOsmol / L, for example 30.5 to 150 mOsmol / L.

[0248] 6. The method according to technical solution 5, wherein the reduction in the osmolarity of the buffer solution comprises a linear reduction or a stepwise reduction.

[0249] 7. The method according to any one of technical solutions 1 to 6, wherein step (a) comprises disrupting the cytoskeleton of the cell.

[0250] 8. The method according to technical solution 7, wherein the cytoskeleton of the cell is disrupted by contacting the cell with a cytoskeleton-disrupting reagent.

[0251] 9. The method according to technical solution 8, wherein the cytoskeleton disrupting reagent comprises a microfilament depolymerizing agent selected from, for example, latrunculin A, latrunculin B, cytochalasin A, cytochalasin B, cytochalasin C, cytochalasin D, and cytochalasin E.

[0252] 10. The method according to any one of technical solutions 1 to 9, wherein step (a) includes inhibiting the cell volume regulatory function of the cell.

[0253] 11. The method according to technical solution 10, wherein the cell volume regulatory function of the cell is inhibited by inhibiting the expression or activity of a cell volume regulatory protein in the cell.

[0254] 12. The method according to technical solution 11, wherein the cell volume regulatory protein is selected from ion channels and transporters.

[0255] 13. The method according to technical solution 12, wherein the cell volume regulatory protein is selected from volume-regulated anion channels (VRACs), such as SWELL1; volume-regulated cation channels (VRCCs), such as TRPV4 and TRPM3; and cotransporters, such as KCC1, KCC3, and KCC4.

[0256] 14. The method according to technical solution 10, wherein the cell volume regulation function of the cells is inhibited by placing the cells in a buffer containing cations or anions that have a reduced ability to regulate changes in cell volume.

[0257] 15. The cation is K + , Na + , Cs + , Li + , Ca 2+ , Mg 2+ , B.A. 2+ , Mn 2+ , Fe 2+ , Ni 2+ , Zn 2+ , Al 3+ , Fe 3+ , CH3NH3 + , C2H5NH3 + , (CH3)2NH2 + , (C2H5)2NH2 + , (C2H5)3N + 15. The method according to technical solution 14, wherein the cations are selected from one or more of: ammonium ions, and / or choline ions.

[0258] 16. The anion is Br - , Cl- , I - , F - , O.H. - , HCO 3- , H2PO4 - , NO2 - , NO3 - , C.N. - , HPO4 2- , CO3 2- , SO4 2- , and / or PO4 3- The method according to technical solution 14, selected from one or more of the following:

[0259] 17. The method according to any one of technical solutions 1 to 16, wherein step (a) comprises causing the cell to overexpress one or more proteins selected from members of the tetraspanin family.

[0260] 18. The members of the tetraspanin family are Tspan1, Tspan2, Tspan3, Tspan4, Tspan5, Tspan6, Tspan7, Tspan8, Tspan9, Tspan10, Tspan11, Tspan12, Tspan13, Tspan14, Tspan15, Tspan16, Tspan17, Tspan18, Tspan19, Tspan20 (UPK1B), Tsp The method according to technical solution 17, comprising an21 (UPK1A), Tspan22 (PRPH2), Tspan23 (ROM1), Tspan24 (CD151), Tspan25 (CD53), Tspan26 (CD37), Tspan27 (CD82), Tspan28 (CD81), Tspan29 (CD9), Tspan30 (CD63), Tspan31, Tspan32, and Tspan33.

[0261] 19. The method according to technical solution 17, wherein step (a) comprises overexpressing Tspan4 in the cell.

[0262] 20. The method according to any one of technical solutions 1 to 19, further comprising reducing the size of the engineered migrasomes.

[0263] 21. The method according to technical solution 20, wherein the size of the engineered migrasomes is reduced by extruding the engineered migrasomes using a filter of a specific pore size, and optionally the size of the reduced engineered migrasomes is in the nanoscale, for example 50-200 nm.

[0264] 22. The method according to any one of technical solutions 1 to 21, wherein the cell is a normal cell or a cancer cell.

[0265] 23. An engineered migrasome produced by the method according to any one of technical solutions 1 to 22.

[0266] 24. A delivery system comprising isolated or purified migrasomes and a cargo, wherein the cargo is directly or indirectly incorporated into the membrane of the migrasome.

[0267] 25. The delivery system according to technical solution 24, wherein the migrasomes are selected from naturally occurring migrasomes and artificially derived engineered migrasomes.

[0268] 26. A delivery system according to technical solution 25, wherein the engineered migrasomes are produced by a method according to any one of technical solutions 1 to 22.

[0269] 27. A delivery system according to any one of technical solutions 24 to 26, wherein the cargo is selected from proteins, such as membrane proteins and soluble proteins, peptides, nucleic acids, such as DNA and RNA, and small molecule compounds.

[0270] 28. The delivery system according to any one of technical solutions 24 to 26, wherein the cargo is selected from therapeutic proteins, immunogenic proteins, cytokines, enzymes, siRNAs, microRNAs, antisense oligonucleotides (ASOs), mRNAs, CRISPR systems, cytotoxic agents, therapeutic small molecules, and targeting molecules.

[0271] 29. The delivery system according to technical solution 28, wherein the targeting molecule is selected from: an antibody or an antigen-binding fragment thereof; an integrin; a find-me / eat me signal such as PAMPs and DAMPs; and a don't-eat-me signal such as CD47 and CD24.

[0272] 30. A delivery system according to any one of technical solutions 24 to 29, wherein the cargo is incorporated or intercalated into the membrane of the migrasome by physical adsorption or chemical binding.

[0273] 31. Cargo, (1) conjugation to membrane components such as migrasome membrane proteins or cholesterol; (2) conjugating, preferably by click chemistry, to a protein or peptide bound to the membrane of the migrasome; and (3) conjugating to a first member of a binding pair, wherein the membrane of the migrasome comprises a second member of the binding pair, and the cargo is bound to the membrane of the migrasome by binding between the first member and the second member. The delivery system according to any one of technical solutions 22 to 29, which is incorporated or intercalated into the membrane of the migrasome by a method selected from the group consisting of:

[0274] 32. The delivery system according to technical solution 31, wherein the binding pair comprises a receptor-ligand binding pair.

[0275] 33. The delivery system according to technical solution 32, wherein the binding pair comprises HaloTag and its ligand, or CP05 and CD63.

[0276] 34. The delivery system according to technical solution 31, wherein the cargo is an mRNA, the membrane of the migrasome contains an mRNA-binding protein, and the mRNA binds to the mRNA-binding protein via its protein binding site 3'-UTR and is conjugated to the membrane of the migrasome.

[0277] 35. A delivery system according to any one of technical solutions 24 to 29, wherein the cargo is expressed as a membrane protein on the surface of the membrane of the migrasome.

[0278] 36. A delivery system according to any one of technical solutions 24 to 29, wherein the cargo is expressed on the surface of the membrane of the migrasome as a fusion protein fused to a membrane protein or part thereof.

[0279] 37. A method for producing a delivery system comprising isolated or purified migrasomes and a cargo selected from the group consisting of proteins, peptides, nucleic acids (e.g., DNA and RNA), and small molecule compounds, comprising: Isolating or purifying migrasomes from cells, the migrasomes being natural migrasomes or artificially derived engineered migrasomes; and The method comprises directly or indirectly binding a cargo to the membrane of a migrasome, thereby producing a delivery system.

[0280] 38. The method according to technical solution 37, wherein the cargo is incorporated into the membrane of the migrasome by physical adsorption or chemical binding.

[0281] 39. Cargo, (1) conjugating the cargo to a membrane component such as a migrasome membrane protein or cholesterol; (2) conjugating the cargo, preferably by click chemistry, to a protein or peptide bound to the membrane of the migrasome; The method according to technical solution 37, wherein the method is incorporated into the membrane of the migrasome by a method selected from the group consisting of:

[0282] 40. A method of producing a delivery system comprising engineered migrasomes and a cargo selected from the group consisting of proteins, peptides, nucleic acids (e.g., DNA and RNA), and small molecule compounds, wherein the cargo is conjugated to a first member of a binding pair and the membrane of the migrasome comprises a second member of the binding pair, the method comprising: causing the cell to express on the cell membrane a second member of the binding pair; Producing, by the cell, an engineered migrasome having a membrane that includes a second member of the binding pair; and A method comprising contacting a complex of a cargo and a first member of a binding pair with an engineered migrasome, thereby producing a delivery system by binding of the first member to the second member.

[0283] 41. The method according to technical solution 40, wherein the binding pair comprises a receptor-ligand binding pair.

[0284] 42. The method according to technical solution 41, wherein the binding pair comprises HaloTag and its ligand, or CP05 and CD63.

[0285] 43. A method for producing a delivery system comprising an engineered migrasome and a cargo, the cargo being an mRNA, the membrane of the migrasome comprising an mRNA-binding protein, the mRNA being conjugated to the mRNA-binding protein via its protein-binding site 3'-UTR, the method comprising: causing the cell to express the mRNA; The method includes, before, after, or simultaneously with the above steps, causing the cell to express an mRNA-binding protein on the cell membrane, and producing, by the cell, a delivery system comprising an engineered migrasome and an mRNA, wherein the mRNA is conjugated to the membrane of the engineered migrasome by binding to the mRNA-binding protein.

[0286] 44. A method of producing a delivery system comprising engineered migrasomes and a cargo, the cargo being a protein and expressed on the surface of the membrane of the engineered migrasome, the method comprising: causing a cell to express a protein on the cell membrane; and A method comprising producing, by a cell, a delivery system comprising an engineered migrasome and a protein expressed on a membrane surface of the engineered migrasome.

[0287] 45. The method according to technical solution 44, wherein the protein is a membrane protein.

[0288] 46. ​​The method according to technical solution 44, wherein the protein is a soluble protein and is expressed on the surface of the membrane of the migrasome as a fusion protein fused to a membrane protein or part thereof.

[0289] 47. The method according to any one of technical solutions 37 to 46, wherein the engineered migrasomes are produced by the method according to any one of technical solutions 1 to 22.

[0290] Compared with drug-conjugated delivery systems and non-biological drug delivery systems, the migrasome delivery system of the present application has better biocompatibility, more cargo types, larger capacity, and easier membrane modification to enhance or change targeting. Compared with engineered exosomes and engineered red blood cells, the migrasome delivery system retains high biocompatibility and ease of modification, but migrasomes are larger than traditional small vesicles (such as exosomes) so that drugs, especially high molecular weight proteins and nucleic acids, can be delivered more efficiently. Meanwhile, the migrasome delivery system is highly modifiable, and the size of the migrasome and the substances loaded on the membrane can be adjusted according to the drug that needs to be delivered and the cells that need to be targeted. Migrasomes also have the advantage of low toxicity, making it easier to convert and modify membrane components. In addition, the production of engineered migrasomes does not require ultra-high speed centrifugation or blood extraction every time, greatly reducing the production time and cost.

[0291] Therefore, compared with existing drug delivery systems, the migrasome delivery system of the present application has the characteristics of low toxicity, high capacity, ease of modification, rapid production, and low cost, has a unique antigen presentation effect due to tunable antigenicity, and can be used as a vaccine delivery platform.

[0292] Applicants have found that cells can be induced to produce engineered migrasomes by treating the cells with one or more of the following: administering hypotonic treatment, disrupting the cytoskeleton of the cells, inhibiting the cell volume regulatory function of the cells, and causing the cells to overexpress a member of the tetraspanin family, modulating the relative movement of the cells by rapid detachment from a surface or cell membrane.

[0293] Migrasomes have a vesicular structure, but are different from other extracellular vesicles, including exosomes. Migrasomes do not necessarily belong to extracellular vesicles in the strict sense. Although migrasomes detached from cells are extracellular vesicles, many functions of migrasomes are accomplished before detachment from the cell body. This is why migrasomes are considered organelles rather than simply extracellular vesicles. The production of extracellular vesicles (exfoliated migrasomes) is only one of the many functions of migrasomes.

[0294] Exfoliated migrasomes are a type of extracellular vesicle and show many differences from exosomes, such as: 1) different structure: migrasomes exhibit a structure with small vesicles bound to retraction fibers and contained in large vesicles before being released, whereas exosomes do not; 2) different size: exosomes have a diameter of about 50-150 nm, whereas migrasomes have a diameter of about 0.5-3 μm; 3) obviously different protein composition: migrasomes and exosomes share only 27% of their protein composition, e.g., NDST1 (bifunctional heparan sulfate N-deacetylase / N-sulfotransferase 1), PIGK (phosphatidylinositol glycan anchor biosynthesis class K), CPQ (carboxypeptidase Q), and EOGT (EGF domain-specific O-linked N-acetylglucosamine transferase) are enriched on migrasomes but not in exosomes (Zhao X, Lei Y, Zheng J,Peng J,Li Y,Yu L,Chen Y.Identification of markers for migrasome detection.Cell Discov.2019 May 21;5:27); and 4) completely different biogenesis processes resulting from regulation by different genetic pathways: exosomes are initially produced as vesicles in multivesicular bodies (MVBs) and are released upon fusion of the MVBs to the plasma membrane, whereas migrasomes are formed by the assembly of large domains on the plasma membrane (Huang Y,Zucker B,Zhang S,Elias S,Zhu Y,Chen H,Ding T,Li Y,Sun Y,Lou J,Kozlov MM*,Yu L*.Migrasome formation is mediated by assembly of micron-scale tetraspanin macrodomains.Nat Cell Biol.2019 Aug;21(8):991-1002).

[0295] As used herein, the term "engineered migrasomes" refers to migrasomes obtained by engineering and / or artificial derivation of cells. It should be noted that "engineered migrasomes" may not be meant to be synthetic, but are still derived from cells.

[0296] The engineered migrasomes of the present application may differ from "hypotonicity-induced vesicles" known in the art (e.g., vesicles as shown in FIG. 1, Cohen S, Ushiro H, Stoscheck C, Chinkers MA native 170 000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J Biol Chem 257:1523-1531). They have at least the following differences: 1) different vesicle production sites: engineered migrasomes are produced on the retraction fibers around the cells, whereas vesicles are produced on the top surface of the cells according to Cohen et al.; 2) different vesicle sizes: engineered migrasomes have a micron-level size and a diameter rarely exceeding 5 μm, whereas vesicles induced by Cohen et al. using hypoosmotic pressure can be as large as 20 μm; and 3) unlike the method of hypotonic induction by Cohen et al., hypotonicity may not be required for the production of engineered migrasomes in the present application, and by adjusting the adhesive properties of the cells, the cells can be rapidly detached to allow relative movement of the cell membrane on the attached surface, thereby inducing migrasomes.

[0297] Unless expressly stated otherwise, migrasomes herein may include both naturally occurring migrasomes and artificially derived engineered migrasomes.

[0298] In some embodiments, isolated or purified migrasomes may have no detectable contaminant components or have levels or amounts of contaminant components below acceptable levels or amounts.

[0299] In some embodiments, engineered migrasomes may be isolated and / or purified by centrifugation. For example, engineered migrasomes may be isolated and / or purified by centrifugation at 300-17000×g. In some embodiments, engineered migrasomes may be isolated and / or purified by filtration.

[0300] Applicant has found that hypotonic treatment of cells can induce rapid and abundant formation of micron-sized vesicles on the retraction fibers of cells. Such micron-sized vesicles are artificially induced engineered migrasomes. Thus, in some embodiments of the method of making engineered migrasomes of the present application, inducing cells to produce engineered migrasomes may include subjecting the cells to hypotonic treatment. In some embodiments, the hypotonic treatment may be performed by placing the cells in a hypotonic buffer having an osmolality of 10%-90% of an isotonic buffer, such as 15%-85%, 20%-80%, 25%-75%, 30%-70%, 35%-65%, 40%-60%, or 50%-55% of an isotonic buffer, or any value or subrange therebetween, such as 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% of an isotonic buffer. In some other embodiments, the hypotonic treatment may be performed by placing the cells in a buffer and decreasing the osmolality of the buffer. In some embodiments, the decrease in the osmolality of the buffer comprises a linear decrease or a stepwise decrease. For example, in some embodiments, the salt concentration of the buffer may be decreased stepwise at predetermined intervals. For example, the salt concentration of the buffer may be decreased stepwise at least three times (eg, 3 to 5 times) by ⅙ to ½ each time.

[0301] Applicant has also found that disrupting the cytoskeleton causes cells to shrink and retract the edges of the cells toward the center while the cells adhere to various points on the bottom of the culture plate via focal adhesions, thereby attaching the plasma membrane in situ as an anchor for membrane tether formation. The shrinkage of the cells results in the mass formation of membrane tethers on the areas occupied by the cells prior to shrinkage, and these newly formed membrane tethers greatly enhance the formation of engineered migrasomes. Thus, in some embodiments, inducing cells to produce engineered migrasomes may include disrupting the cytoskeleton of the cells. In some embodiments, the cytoskeleton of the cells may be disrupted by contacting the cells with a cytoskeleton disrupting reagent. In some embodiments, the cytoskeleton disrupting reagent comprises a microfilament or microtubule depolymerizing agent selected from, for example, latrunculin A, latrunculin B, cytochalasin A, cytochalasin B, cytochalasin C, cytochalasin D, and cytochalasin E. In some embodiments, the cytoskeleton disrupting reagent is latrunculin A. In some embodiments, the concentration of the cytoskeleton disrupting reagent may be any suitable concentration. For example, the concentration of the microfilament and / or microtubule depolymerizing agent may be at least 0.01 μM, at least 0.1 μM, at least 0.2 μM, at least 0.5 μM, at least 1 μM, at least 2 μM, at least 3 μM, at least 4 μM, at least 5 μM, at least 6 μM, at least 7 μM, at least 8 μM, at least 9 μM, or at least 10 μM.

[0302] Cells can withstand changes in osmotic pressure through their regulated volume changes. Thus, suppressing cell volume regulatory functions can promote the formation of engineered migrasomes. In some embodiments, inducing cells to produce engineered migrasomes may include suppressing cell volume regulatory functions of the cells. In some embodiments, the cell volume regulatory functions of the cells may be suppressed by suppressing the expression or activity of cell volume regulatory proteins in the cells. For example, the cell volume regulatory proteins may be selected from ion channels and transporters. In some embodiments, the cell volume regulatory proteins may be selected from volume-regulated anion channels (VRACs), such as SWELL1; volume-regulated cation channels (VRCCs), such as TRPV4 and TRPM3; and cotransporters, such as KCC1, KCC3, and KCC4. Protein expression or activity may be inhibited by any method or reagent known in the art, such as disruption of the gene sequence encoding the protein, RNAi, protein activity inhibitors, and the like.

[0303] It is known that cations and anions can regulate cell volume, but different ions have different abilities to regulate cell volume changes. Thus, ions with a weaker ability to regulate cell volume changes are also weaker in withstanding osmotic pressure changes so that migrasome formation is promoted. Thus, in some embodiments, the cell volume regulation function of a cell may be inhibited by placing the cell in a buffer containing a cation or anion with a reduced ability to regulate cell volume changes. As used herein, the term "reduced ability to regulate cell volume changes" refers to a cation (e.g., sodium ion) or anion that confers normal cell volume regulation ability to the cell.

[0304] In some embodiments, inducing cells to produce engineered migrasomes may include overexpressing in the cells one or more proteins selected from tetraspanin family members or key enzymes and structural proteins of the migrasome production pathway, or stimulating with a migrasome production agonist. For example, tetraspanin family members include Tspan1, Tspan2, Tspan3, Tspan4, Tspan5, Tspan6, Tspan7, Tspan8, Tspan9, Tspan10, Tspan11, Tspan12, Tspan13, Tspan14, Tspan15, Tspan16, Tspan17, Tspan18, Tspan19, Tspan20 (UPK1 B), Tspan21 (UPK1A), Tspan22 (PRPH2), Tspan23 (ROM1), Tspan24 (CD151), Tspan25 (CD53), Tspan26 (CD37), Tspan27 (CD82), Tspan28 (CD81), Tspan29 (CD9), Tspan30 (CD63), Tspan31, Tspan32, and Tspan33. In some embodiments, cells may be induced to produce engineered migrasomes by overexpressing one or more Tspan proteins in the cells.

[0305] In some embodiments, migrasomes may be induced by adjusting the cell adhesion properties to allow the cells to rapidly detach, reducing the contact area between the cells and the culture surface, or by relative movement between the cell membrane and the surface. The cells may be subjected to hypotonic treatment at 4°C, 8°C, 16°C, 24°C, or 37°C, or the cell detachment process may be performed at 4°C, 8°C, 16°C, 24°C, or 37°C without hypotonic treatment. Also, the cell body and migrasomes may be separated.

[0306] In some embodiments, the method of making engineered migrasomes of the present application further comprises reducing the size of the engineered migrasomes. The size of the engineered migrasomes may be reduced by any means known in the art, for example, by extruding the engineered migrasomes using a filter or extruder with a specific pore size. In some embodiments, the size of the engineered migrasomes may be reduced by processing the engineered migrasomes using an extruder with a filter membrane with a specific pore size. In some embodiments, the pore size of the filter membrane or extruder may be 30 nm to 10,000 nm, e.g., 50 nm to 8,000 nm, 50 nm to 1000 nm, 50 nm to 10,000 nm, 100 nm to 1000 nm, 100 nm to 10,000 nm, 1000 nm to 10,000 nm, 10 to 400 nm, 20 to 300 nm, 30 to 200 nm, 40 to 100 nm, 50 to 80 nm, or any value or subrange therebetween. In some embodiments, the size of the reduced engineered migrasomes may be nanoscale, e.g., 1-1000 nm, 10-900 nm, 20-300 nm, 30-200 nm, 40-100 nm, 50-80 nm, or any value or subrange therebetween.

[0307] The cells used to produce engineered migrasomes herein may be any cells, such as in vitro cultured cells or in vivo cells; suspension or adherent cultured cell lines / lines with or without modification in suspension or adherent state, normal cells, primary cells, or disease-derived cells including cancer cells. Furthermore, the cells used to produce engineered migrasomes may be derived from any cell line suitable for in vitro growth, modification, and expression of exogenous molecules and production of engineered migrasomes. In some embodiments, the cells may be animal cells, particularly mammalian cells including mouse and human cells. Examples of suitable cells include, but are not limited to, normal rat kidney cells (NRK cells), mouse fibroblasts such as NIH3T3 cells, mouse breast carcinoma 4T1 cells, mouse colon carcinoma MC38 cells, commonly used human embryonic kidney (HEK) cell lines / strains such as HEK293 or HEK293FT cells, human gastric carcinoma MGC-803 cells, human T lymphocytoma Jurkat cells, human dermal fibroblast BJ cells, Chinese hamster ovary (CHO) cells, mesenchymal stem cells (MSC), or any other suitable cells.

[0308] As used herein, the term "cargo" may refer to any substance that can be loaded onto a migrasome and thereby efficiently delivered. For example, the cargo may be delivered to a target cell by an interaction between a surface molecule of the migrasome and the target cell. One or more of the cargoes of the present application may be loaded onto the membrane of an engineered migrasome during or after the formation of the engineered migrasome, or may be loaded directly onto the membrane of a native migrasome. Examples of cargo include, but are not limited to, therapeutic agents, such as synthetic bioactive compounds, natural bioactive compounds, antibacterial compounds, antiviral compounds, proteins or peptides (e.g., enzymes or antibodies), nucleotides (e.g., nucleotides containing a detectable moiety or toxin, or nucleotides that disrupt transcription), nucleic acids (e.g., DNA or mRNA molecules encoding peptides such as enzymes, pathogenic proteins, cytokines, tumor suppressor genes, antibodies, etc., or RNA molecules with regulatory functions, such as microRNAs, dsDNA, antisense oligonucleotides (ASOs), lncRNAs, and siRNAs), genome editing systems, lipids, carbohydrates, small molecules (e.g., small molecule drugs and toxins), targeting molecules, polysaccharides, complexes, organelles, nanoparticles and microparticles, or any combination thereof.

[0309] In some embodiments, the cargo may be a microRNA or siRNA, for example, a microRNA or siRNA that specifically binds to transcripts encoding mutated or non-mutated cancer genes. The binding of the microRNA or siRNA may be mRNA decoding and protein synthesis. Such genes include, but are not limited to, ABLI, BLC1, BCL6, CBFA1, CBL, CSFIR, ERBA, ERBB, EBRB2, ETS1, ETS1, ETV6, FGR, FOX, FYN, HCR, HRAS, JUN, KRAS, LCK, LYN, MDM2, MLL, MYB, MYC, MYCL1, MYCN, NRAS, PIM1, PML, RET, SRC, TAL1, TCL3, YES, VEGF, FGF, G-CSF, CXCR4, etc.

[0310] In some embodiments, the cargo may be a genome editing system. Genome editing systems include, but are not limited to, long-range nuclease systems, zinc finger nuclease (ZFN) systems, transcription activator-like effector nuclease (TALEN) systems, and clustered regularly interspaced short palindromic repeats (CRISPR) systems. In some embodiments, the cargo may be a CRISPR system. In some embodiments, the CRISPR system may be a CRISPR-Cas9 system. The CRISPR-Cas9 system includes a nucleotide sequence encoding a Cas9 protein, a nucleotide sequence encoding a CRISPR RNA (crRNA) hybridized to a target sequence, and a nucleotide sequence encoding a transactivating CRISPR RNA (tracrRNA). The crRNA and tracrRNA may be fused to a guide RNA. The CRISPR-Cas9 system may further include a nuclear localization signal (NLS). Migrasomes loaded with the CRISPR-Cas9 system may be used to alter gene expression and function in disease management, regenerative medicine, and tissue engineering.

[0311] In some embodiments, the cargo may be a therapeutic protein or a fragment thereof, such as an antibody or a fragment thereof. In some embodiments, the cargo may be a protein (including an antibody or antibody fragment, an immunogenic protein, a cytokine, an enzyme, a tumor suppressor gene product, etc.) or a fragment thereof, such as chicken ovalbumin (OVA), the SARS-CoV-2 spike protein or an S1 fragment thereof.

[0312] In some embodiments, the cargo may be a targeting molecule. As used herein, the term "targeting molecule" refers to a molecule that can specifically bind to another molecule (the target molecule). For example, a targeting molecule may be used to specifically target migrasomes and present the targeting molecule on its surface to an entity, such as a tissue or cell that expresses the target molecule, thereby improving the targeting of the delivery system. In some embodiments, the delivery system of the present application may include at least two different targeting molecules to further improve targeting specificity or otherwise improve targeting to the target cell or tissue. For example, the targeting molecule may specifically bind to a surface protein that is overexpressed on cancer cells, such as an antibody or an antigen-binding fragment thereof. In some embodiments, the targeting molecule may be selected from an antibody or an antigen-binding fragment thereof; an integrin; a cytokine, a chemokine, and / or a cytokine, a chemokine receptor; a polysaccharide; find-me / eat me signals such as PAMPs and DAMPs; and don't-eat-me signals such as CD47 and CD24. In some embodiments, an antibody or antigen-binding fragment thereof may bind to its corresponding antigen, thereby delivering migrasomes loaded with the antibody or antigen-binding fragment thereof to target cells expressing the corresponding antigen. In some embodiments, an integrin or other targeting molecule may be paired with a tissue-specific extracellular matrix, thereby achieving targeting of specific organs by migrasomes loaded with integrins or other targeting molecules.

[0313] As used herein, the term "find-me / eat-me signal" refers to a signal that is exposed or released by apoptotic cells to induce phagocytic uptake, thereby activating tolerance pathways to prevent immune responses against self-antigens. The find-me / eat-me signal herein is loaded onto migrasomes, and the find-me / eat-me signal can be recognized by macrophages and the like so that the migrasomes are phagocytosed by certain cells. Exemplary find-me / eat-me signals include, for example, pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). "Pathogen-associated molecular patterns (PAMPs)" refer to evolutionarily conserved constant molecular structures that are present on the surface of pathogenic microorganisms and are absent in some human hosts but may be shared by many related microorganisms. PAMPs recognized by innate immunity are often the main parts that pathogens depend on for survival and therefore are less variable, such as double-stranded RNA in viruses and lipopolysaccharide in bacteria. This makes it difficult for pathogens to mutate and escape the effects of innate immunity. PAMPs can be expressed on the surface of pathogens or outside immune cells, or can be found in the cytosol of immune cells, as well as in various intracellular compartments that carry pathogens (such as endosomes and phagolysosomes). There are two main categories of PAMPs. The first category includes bacterial cell wall components dominated by sugars and lipids, such as lipopolysaccharides, peptidoglycans, lipoteichoic acids, mannose, lipids, lipoarabinomannans, lipoproteins, and flagellins. The most common and representatives in this category include lipopolysaccharides (LPS) produced by gram-negative bacteria; peptidoglycans produced by gram-positive bacteria; glycolipids produced by mycobacteria, and mannose produced by yeast. The first category includes viral products and bacterial nuclear components, such as unmethylated oligonucleotides CpGDNA, single-stranded RNA, and double-stranded RNA. "Damage-associated molecular patterns (DAMPs)" are a type of substance that is released into the intercellular space or blood circulation after tissues or cells are stimulated by injury, hypoxia, stress, and other factors.They can induce autoimmunity or immune tolerance through pattern recognition receptors such as Toll-like receptors, RIG-1-like receptors, or NOD-like receptors, and play an important role in the development and progression of diseases such as arthritis, atherosclerosis, tumors, and systemic lupus erythematosus. DAMPs are present in the cell nucleus, cytoplasm (e.g., high mobility group box (HMGB) 1 and S100 proteins), extracellular matrix (e.g., hyaluronic acid), and plasma (e.g., complements C3a, C4a, and C5a), or as foreign bodies (e.g., heat shock proteins). Non-protein forms of DAMPs include adenosine triphosphate, uric acid, heparin sulfate, RNA, and DNA. These proteins and non-proteins are trapped inside cells in healthy conditions and are released outside the cells when they are destroyed.

[0314] As used herein, the term "don't-eat-me signal" refers to a signal expressed by a tumor cell on its surface, which binds to a ligand on the surface of an immune cell and inhibits the killing effect of the immune cell against the tumor cell. Exemplary don't-eat-me signals include, for example, CD47 and CD24. The don't-eat-me signal herein is loaded onto the migrasome by gene editing, membrane fusion, etc., so that the migrasome avoids immune system clearance and extends its circulation time in the blood, thereby achieving better tissue infiltration.

[0315] For example, migrasomes may have a unilamellar membrane structure with membranes derived from the cell membrane and intracellular vesicles. Compared to the cell membrane, the membrane of migrasomes is specifically enriched with certain proteins (e.g., tetraspanins) and lipids (e.g., cholesterol and sphingomyelin).

[0316] The cargo of the present application may be incorporated or intercalated into the membrane and / or interior of migrasomes directly or indirectly by any means known in the art.

[0317] In some embodiments, cargo may be incorporated or intercalated into the membrane and / or interior of migrasomes by liquid-solid conversion, membrane fusion, charge adsorption, physical adsorption, or chemical binding.

[0318] In other embodiments, the cargo may be incorporated or intercalated into the membrane and / or interior of the migrasome by a means selected from the group consisting of: (1) conjugation to a component such as a membrane protein, cholesterol, phospholipid, carbohydrate chain on a glycoprotein, or polysaccharide in the membrane and / or interior of the migrasome; (2) conjugation to a protein or peptide, carbohydrate chain on a glycoprotein or polysaccharide, phospholipid, cholesterol, etc. incorporated into or intercalated into the membrane and / or interior of the migrasome, where the protein or peptide, carbohydrate chain on a glycoprotein or polysaccharide, phospholipid, cholesterol, etc. is incorporated into or intercalated into the membrane and / or interior of the migrasome, preferably by click chemistry; and (3) conjugation to a first member of a binding pair, where the membrane and / or interior of the migrasome includes a second member of the binding pair, and the cargo is incorporated into or intercalated into the membrane and / or interior of the migrasome by binding between the first and second members.

[0319] In some embodiments, the cargo is incorporated or intercalated in the membrane and / or interior of the migrasome by conjugating to a component such as a protein or lipid in the membrane and / or interior of the migrasome. In some embodiments, the cargo is incorporated or intercalated in the membrane and / or interior of the migrasome by binding to a membrane protein such as a tetraspanin in the migrasome. In some embodiments, the cargo is incorporated or intercalated in the membrane and / or interior of the migrasome by conjugating to a tetraspanin protein. In some embodiments, the cargo is incorporated or intercalated in the membrane and / or interior of the migrasome by conjugating to a lipid (e.g., cholesterol and sphingomyelin), a protein or peptide, a carbohydrate chain on a glycoprotein, or a polysaccharide in the membrane of the migrasome.

[0320] In some embodiments, the binding pair includes antigen-antibody, receptor-ligand, biotin-avidin, HaloTag and its ligand, or other binding pairs. For example, the binding pair includes HaloTag and its ligand, or CP05 and CD63.

[0321] In some embodiments, the cargo is an mRNA, the membrane or interior of the migrasome contains an mRNA-binding protein, and the mRNA is incorporated or intercalated into the membrane and / or interior of the migrasome by binding of its protein-binding site to the mRNA-binding protein. The mRNA-binding protein and its protein-binding site may be any known in the art. For example, in some embodiments, the mRNA-binding protein is L7Ae, and the protein-binding site is the C / D box. In some other embodiments, the mRNA-binding protein is MS2BP, and the protein-binding site is the MS2 stem-loop (MS2SL).

[0322] In some other embodiments, the cargo may be expressed on the inner or outer surface of the migrasome membrane as a fusion protein. In some other embodiments, the cargo may be expressed on the inner or outer surface of the migrasome membrane as a fusion protein fused to a membrane protein or a portion thereof. Any membrane protein known in the art may be used as a membrane-anchored protein fused to a soluble protein. Examples of membrane proteins for fusion of soluble proteins include, but are not limited to, cell receptors, ion channels, transporters, etc., such as Tspan-4, CD81, CD9, CD63, PDGFR, Lamp2b, syntaxin 2 (STX2), etc. In some embodiments, the membrane protein for fusion of soluble proteins may be STX2. In some embodiments, the membrane protein for fusion of soluble proteins may be truncated STX2 (t-STX2). For example, the N-terminus of STX2 may be modified to remove its intracellular terminal function to obtain t-STX2. Soluble proteins can then be attached to the extracellular C-terminus of t-STX2 to form soluble protein-t-STX2 fusion proteins, and the soluble proteins can be expressed on the membrane of migrasomes as artificial plasma membrane-localized fusion proteins.

[0323] In another aspect, the present application relates to a method for producing a delivery system comprising isolated or purified migrasomes and a cargo, wherein the cargo is selected from the group consisting of proteins, peptides, nucleic acids (e.g., DNA and RNA), lipids, small molecule compounds, polysaccharides, complexes, nano / microparticles, and organelles, or multiple of the aforementioned cargoes are simultaneously loaded, the method comprising isolating or purifying migrasomes from cells, wherein the migrasomes are natural migrasomes or artificially derived engineered migrasomes, and directly or indirectly incorporating or intercalating the cargo into the membrane and / or interior of the migrasome. In some embodiments of the method for producing a delivery system of the present application, the cargo is incorporated into or intercalated into the membrane and / or interior of the migrasome by liquid-solid conversion, membrane fusion, charge adsorption, physical adsorption, or chemical binding.

[0324] In some other embodiments of the methods of producing the delivery system of the present application, the cargo is incorporated or intercalated into the membrane and / or interior of the migrasome by a means selected from the group consisting of: (1) conjugation of the cargo to a component such as a membrane protein, cholesterol, phospholipid, carbohydrate chain on a glycoprotein or polysaccharide in the membrane and / or interior of the migrasome; and (2) conjugation of the cargo to a protein or peptide, carbohydrate chain on a glycoprotein or polysaccharide, phospholipid, cholesterol, etc. bound to the membrane and / or interior of the migrasome, wherein the protein or peptide, carbohydrate chain on a glycoprotein or polysaccharide, phospholipid, cholesterol, etc. is incorporated or intercalated into the membrane and / or interior of the migrasome, preferably by click chemistry.

[0325] In some embodiments, naturally occurring migrasomes may be isolated or purified from cells by methods known in the art. In some embodiments, artificially derived engineered migrasomes are produced by the methods of making engineered migrasomes disclosed herein. In some embodiments, the cargo may be one or more of the cargos described elsewhere herein.

[0326] In another aspect, the application relates to a method of producing a delivery system comprising engineered migrasomes and a cargo, wherein the cargo is selected from the group consisting of proteins, peptides, nucleic acids (e.g., DNA and RNA), lipids, small molecule compounds, polysaccharides, complexes, nano / microparticles, and organelles, or a plurality of the aforementioned cargoes are simultaneously loaded, wherein the cargo is conjugated to a first member of a binding pair and the membrane or interior of the migrasome comprises a second member of the binding pair, the method comprising causing a cell to express the second member of the binding pair on the cell membrane, producing by the cell engineered migrasomes having a membrane comprising the second member of the binding pair, and contacting the complex of the cargo and the first member of the binding pair with the engineered migrasome, thereby producing a delivery system by binding of the first member with the second member.

[0327] In some embodiments of the method of producing a delivery system of the present application, the method comprises introducing a nucleotide sequence comprising a coding sequence for a second member of a binding pair into a cell, causing the cell to express the second member of the binding pair. In some embodiments, the method comprises introducing a nucleotide sequence comprising a coding sequence for the second member of the binding pair into a cell, and culturing the cell under conditions that cause the cell to express the second member of the binding pair, such that the cell expresses the second member of the binding pair on the cell membrane.

[0328] In some embodiments, the method comprises: a) introducing into a cell a nucleotide sequence comprising a coding sequence for a second member of the binding pair; b) culturing the cell under conditions that cause the cell to express the second member of the binding pair; c) producing by the cell an engineered migrasome comprising the second member of the binding pair on its membrane; d) conjugating a cargo to the first member of the binding pair to form a complex; and e) contacting the engineered migrasome with the complex to produce a delivery system. In some embodiments, step d) is performed before, after, or simultaneously with step a).

[0329] In some embodiments, the second member of the binding pair is a membrane protein or a soluble protein. In some embodiments, the second member of the binding pair is a membrane protein and is expressed on the inner or outer surface of the membrane of the migrasome. In some embodiments, the second member of the binding pair is a soluble protein and is expressed on the inner or outer surface of the membrane of the migrasome as a fusion protein fused to a membrane protein or a portion thereof.

[0330] In some embodiments, the binding pair comprises antigen-antibody, receptor-ligand, biotin-avidin, HaloTag and its ligand, or other binding pair, hi some embodiments, the binding pair comprises HaloTag and its ligand, or CP05 and CD63.

[0331] In some embodiments, the engineered migrasomes are produced by the methods of making engineered migrasomes disclosed herein, in some embodiments, the cargo may be one or more of the cargos described elsewhere herein.

[0332] In yet another aspect, the application relates to a method of producing a delivery system comprising engineered migrasomes and a cargo, wherein the cargo is mRNA, and wherein the membrane or interior of the migrasome comprises an mRNA binding protein, and wherein the mRNA binds to the mRNA binding protein via its protein binding site, the method comprising: causing a cell to express the mRNA, causing the cell to express the mRNA binding protein on the cell membrane before, after, or simultaneously with the above steps, and producing by the cell a delivery system comprising engineered migrasomes and the mRNA, wherein the mRNA is bound to the membrane and / or interior of the engineered migrasome by binding to the mRNA binding protein.

[0333] In some embodiments of the method of producing the delivery system of the present application, the method comprises introducing into a cell a sequence encoding an mRNA that includes a protein binding site, and causing the cell to express the mRNA.

[0334] In some embodiments, the methods include introducing into the cell a nucleotide sequence comprising a sequence encoding the mRNA binding protein, causing the cell to express the mRNA binding protein on the cell membrane.

[0335] In some embodiments, the method includes introducing into a cell a nucleotide sequence that includes a sequence encoding an mRNA that includes the protein binding site and a sequence encoding the mRNA-binding protein, causing the cell to express the mRNA and the mRNA-binding protein.

[0336] In some embodiments, the mRNA binding protein is a membrane protein or a soluble protein. In some other embodiments, the mRNA binding protein is a membrane protein and is expressed on the inner or outer surface of the membrane of the migrasome. In some other embodiments, the mRNA binding protein is a soluble protein and is expressed on the inner or outer surface of the membrane of the migrasome as a fusion protein fused to a membrane protein or portion thereof.

[0337] The mRNA binding protein and its protein binding site may be known in the art.For example, in some embodiments, the mRNA binding protein is L7Ae and the protein binding site is C / D box.In some other embodiments, the mRNA binding protein is MS2BP and the protein binding site is MS2 stem loop (MS2SL).

[0338] In some embodiments, the engineered migrasomes are produced by the methods of making engineered migrasomes disclosed herein.

[0339] In another aspect, the application relates to a method of producing a delivery system comprising an engineered migrasome and a cargo, wherein the cargo is a protein and is expressed on the inner or outer surface of the membrane of the engineered migrasome, the method comprising causing a cell to express the protein on the cell membrane and producing, by the cell, a delivery system comprising the engineered migrasome and the protein expressed on the inner or outer surface of the membrane of the engineered migrasome.

[0340] In some embodiments, the method includes introducing a nucleotide sequence comprising a sequence encoding a protein into a cell, causing the cell to express the protein on a cell membrane of the cell. In some embodiments, the method includes introducing a nucleotide sequence comprising a sequence encoding a protein into a cell, and culturing the cell under conditions that cause the cell to express the protein, such that the cell expresses the protein on the cell membrane.

[0341] In some embodiments, the method includes introducing into a cell a nucleotide sequence comprising a sequence encoding a protein of interest, culturing the cell under conditions that cause the cell to express the protein of interest, and producing by the cell a delivery system comprising the engineered migrasome and the protein expressed on the inner or outer surface of the membrane of the engineered migrasome.

[0342] In some embodiments, the protein may be a membrane protein, while in some other embodiments, the protein is a soluble protein and is expressed on the surface of the membrane of the migrasome as a fusion protein fused to a membrane protein or portion thereof.

[0343] As described above, examples of membrane proteins for fusion of soluble proteins include, but are not limited to, cellular receptors, ion channels, transporters, such as Tspan-4, CD81, CD9, CD63, PDGFR, Lamp2b, syntaxin 2 (STX2), and the like.

[0344] In some embodiments, the engineered migrasomes are produced by the methods of making engineered migrasomes disclosed herein.

[0345] The present application further provides a pharmaceutical or diagnostic composition comprising the engineered migrasome of the present application in combination with one or more pharma- ceutically acceptable excipients, diluents, or carriers. Accordingly, the present application further provides the use of the engineered migrasome of the present application in making a pharmaceutical composition.

[0346] The present application further provides a method of making a pharmaceutical or diagnostic composition. The method includes adding and mixing the engineered migrasomes of the present application together with one or more pharma- ceutically acceptable excipients, diluents, or carriers. The engineered migrasomes may be used as the sole active ingredient in the pharmaceutical or diagnostic composition or may be accompanied by other active ingredients such as steroids or other drug molecules. The compositions may be administered to a patient individually or in combination (e.g., simultaneously, sequentially, or separately) with other agents, drugs, or hormones.

[0347] A pharmaceutical composition may comprise a therapeutically effective amount of the engineered migrasomes of the present application. In this application, the term "therapeutically effective amount" refers to the amount of a therapeutic agent required to treat, ameliorate, or prevent a targeted disease or condition, or to exert a detectable therapeutic or prophylactic effect. For any publicly available engineered migrasome, the therapeutically effective amount may be estimated first in cell culture assays or animal models, typically rodents, rabbits, dogs, pigs, or primates. Animal models may be used to determine appropriate concentration ranges and routes for administration. The information may then be used to determine appropriate doses and routes for the person to be administered. The exact therapeutically effective amount for a human subject will depend on the severity of the disease or condition, the overall health of the subject, the age, weight, and sex of the subject, diet, timing and frequency of administration, drug combinations, response sensitivities, and tolerability / response to the treatment.

[0348] The pharmaceutical compositions of the present application may be administered by a variety of routes, including, but not limited to, oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intravenous, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, intravaginal, or rectal. The pharmaceutical compositions of the present application may be administered using a needleless injector. In general, the therapeutic compositions may be made into an injectable as a liquid solution or suspension. Solid forms suitable for dissolving or suspending in a liquid medium prior to injection may also be made. Therapeutic doses of pharmaceutical compositions containing engineered migrasomes of the present application do not exhibit significant toxic effects in vivo.

[0349] Without being bound by any theory, the following examples are merely intended to illustrate engineered migrasomes, methods of making and using engineered migrasomes in accordance with the present application, and are not intended to limit the scope of the invention. EXAMPLES

[0350] The present application will be further described below in conjunction with the following specific examples. It should be understood that these embodiments are intended to only illustrate the present application, not to limit the scope of the present application. The experimental methods without specific conditions shown in the following examples generally follow conventional conditions in the art, such as those described in Sambrook, Russeii et al., Molecular Cloning: A Laboratory Manual (Third Edition), CSHL, 2001), or follow the conditions recommended by the manufacturer. Unless otherwise stated, the experimental materials and reagents used in the following examples are commercially available.

[0351] reagent ddH2O (solarbio), KCl (sigma), KH2PO4 (sangon), Na2HPO4-7H2O (sangon), BSA (VWR), latrunculin A (cayman), human fibronectin (invitrogen or sigma), PBS (Gibco), RPMI 1640 (Gibco), FBS (BI), WGA-AF488 / AF594 / AF647 (invitrogen), BCA kit (invitrogen).

[0352] Preparation of 10x KDPBS (500 ml): [Table 1]

[0353] Example 1 Production of engineered migrasomes from cells Example 1. Production of engineered migrasomes by hypotonic treatment The inventors found that hypotonic treatment of cells caused the swelling of the cell body, the retraction of the bottom surface, and the mass production of thread-like structures (retraction fibers), which led to the growth of migrasome-like structures on the retraction fibers. To visually observe the engineered migrasomes, an NRK cell line stably expressing Tspan4-GFP was established, and the formation of engineered migrasomes was observed by the Tspan4 signal, one of the markers of migrasomes. Tspan4-GFP-overexpressing NRK cells were treated with 25% DPBS (equivalent to an osmolarity of 76.3 mOsmol / L), and the results were shown in Figure 1a. The results showed that 30 seconds after hypotonic treatment, the Tspan4-GFP signal began to enrich on the retraction fibers, then formed micron-scale vesicles, and after reaching their peak intensity, the Tspan4-GFP signal began to diffuse from the vesicles accompanied by the shrinkage of the vesicles, and 460 seconds after hypotonic treatment, most of the vesicle structures produced under hypotonic induction had disappeared. The production of these micron-sized vesicles and their binding to retraction fibers was similar to that of native migrasomes.

[0354] To further confirm whether the vesicular structures produced under hypotonic induction were engineered migrasomes, the cells were stained with fluorescently labeled wheat germ lectin (WGA). WGA was a lectin that specifically binds to sialic acid and N-acetyl-D-glucosamine. Fluorescently labeled WGA can be used to label migrasomes in cells and was used as a specific probe to detect migrasomes (Chen et.al.,WGA is a probe for migrosomes,Cell Discovery(2019)5:13).

[0355] Tspan4-GFP-overexpressing NRK cells were subjected to isotonic treatment (100% DPBS, 305 mOsmol / L) and hypotonic treatment (76.3 mOsmol / L) with 25% DPBS, then stained with tetramethylrhodamine-labeled WGA and observed by laser confocal microscopy, as shown in Figure 26c. The results showed that the vesicular structures produced by Tspan4-overexpressing NRK cells under induction were stained by WGA, indicating that the obtained vesicular structures were engineered migrasomes.

[0356] To determine the effect of osmolarity on the formation of engineered migrasomes, Tspan4-GFP-expressing NRK cells were treated with isosmolar (100% DPBS, 305 mOsmol / L) or different hypoosmolar (50%, 25%, and 17% DPBS, corresponding to osmolarities of 152.5, 76.3, and 50.8 mOsmol / L, respectively) conditions. The results are shown in Figure 1b, and the statistical results regarding the diameter of engineered migrasomes are shown in Figure 1c. It was found that the level of osmolarity was negatively correlated with the size of engineered migrasomes, and the lower the osmolarity, the larger the size of the induced engineered migrasomes.

[0357] Based on the above results, we established a protocol to gradually decrease the osmotic pressure and found that the stepwise application of hypotonic treatment significantly increased the persistence of engineered migrasomes, and in cells subjected to five-step hypotonic treatment, the induced engineered migrasomes were retained even after 20 min of hypotonic treatment.

[0358] Example 2: Production of engineered migrasomes by treatment with latrunculin A The number of hypotonicity-induced engineered migrasomes depended on the number of retraction fibers, and most of the plasma membranes as the membrane source of engineered migrasomes were located on the cell body. Therefore, it was speculated that when the cytoskeleton was disrupted and cells contracted, the contraction caused the edges of the cells to retract toward the center, while the cells attached to various points on the bottom of the culture plate via focal adhesions, thereby attaching the plasma membrane in situ as an anchor for membrane tether formation. If this was the case, the contraction of cells would generate numerous membrane tubes in a manner similar to the formation of retraction fibers during migration.

[0359] To test this hypothesis, Tspan4-GFP-expressing NRK cells were incubated with isotonic buffer DPBS containing different concentrations of the microfilament depolymerizing agent latrunculin A (0, 0.25 μM, 0.5 μM, and 1 μM) for 10 min, and then subjected to three consecutive hypotonic stepwise stimulations in which the salt concentration was decreased by 1 / 6 every 2 min by adding water. The results after the stepwise hypotonic treatments are shown in Figure 2a, and the statistical results of the number of engineered migrasomes produced per cell are shown in Figure 2b.

[0360] As expected, it was found that cells shrank when treated with latrunculin A. It was also observed that a large amount of membrane tethers were formed on the area occupied by the cells before shrinkage, and these newly formed membrane tethers significantly enhanced the formation of engineered migrasomes. Thus, latrunculin A could significantly promote the increase in the number of engineered migrasomes, and this promotion was dose-dependent. This suggests that the formation of engineered migrasomes can be promoted by disrupting the cytoskeleton.

[0361] Example 3: Production of engineered migrasomes by suppressing cell volume regulation Cells can tolerate changes in osmolarity through their regulated volume changes. To test whether regulated volume changes affect the formation of engineered migrasomes, we knocked down or out SWELL1, a key component of volume-regulated anion channels that maintain a constant cell volume in response to changes in osmolarity.

[0362] The gene Lrrc8a encoding SWELL1 in Tspan4-GFP expressing NRK cells was knocked down, and the knockdown efficiency for Lrrc8a in the cells was verified by qPCR. The results showed that the gene Lrrc8a encoding SWELL1 was successfully knocked down to about 15% of wild-type cells (Fig. 3a). The cells in which the gene Lrrc8a was knocked down (Lrrc8a-KD) and the control cells without knockdown (NC) were placed in DPBS, respectively, and the cells were subjected to stepwise hypotonic stimulation in three consecutive steps by gradually adding water to reduce the salt concentration by 1 / 3 every 2 min, and then observed by laser confocal microscopy, and the results were shown in Fig. 3b. The statistical results on the size of engineered migrasomes were shown in Fig. 3c.

[0363] We knocked out the gene Lrrc8a encoding SWELL1 in Tspan4-GFP expressing NRK cells. The knockout of Lrrc8a in the cells was verified by Western blotting, and no expression of SWELL1 was observed in the knockout cells (Lrrc8a-KO), indicating that the gene Lrrc8a encoding SWELL1 was successfully knocked out (Fig. 4a). Lrrc8a-KO cells (KO14# and KO18# cell lines) and non-knockout control cells (WT) were placed in DPBS, respectively, and the cells were subjected to stepwise hypotonic stimulation in five consecutive steps by gradually adding water to reduce the salt concentration by 1 / 6 every minute, and then observed by laser confocal microscopy, and the results are shown in Fig. 4b.

[0364] The results showed that after hypotonic treatment, engineered migrasomes produced by Lrrc8a knockdown cells had significantly larger sizes than those produced by non-knockdown cells (Fig. 3b and 3c), and engineered migrasomes produced by Lrrc8a knockout cells also had significantly larger sizes than those produced by non-knockout cells (Fig. 4b). This indicated that knockdown or knockout of SWELL1 significantly enhanced the formation of engineered migrasomes, suggesting that the formation of engineered migrasomes may be enhanced by reducing the ability of cells to regulate their volume during changes in osmotic pressure.

[0365] Cations were known to regulate cell volume. If different cations have different abilities to regulate cell volume during osmotic pressure changes, the regulated cell volume changes may be reduced by the replacement of cations, thereby promoting the formation of engineered migrasomes. Next, the effect of different cations on the formation of engineered migrasomes was tested. The sodium chloride in DPBS was replaced with equimolar concentrations of potassium chloride, cesium chloride, or choline chloride to formulate isotonic buffers containing different cations, and the cells were incubated with these isotonic buffers, respectively, and subjected to stepwise hypotonic stimulation in the corresponding buffers in five consecutive steps by stepwise addition of water to reduce the salt concentration by 1 / 6 every 2 min. The results after stepwise hypotonic treatment are shown in Fig. 5a, and the statistical results of the size of engineered migrasomes are shown in Fig. 5b.

[0366] The results showed that different cations have different abilities to promote the formation of engineered migrasomes, and among the cations tested, sodium ions have a relatively weak ability to promote the formation of engineered migrasomes, whereas potassium ions, cesium ions, and choline ions have a significantly stronger ability to promote the formation of migrasome-like structures.

[0367] Example 4: Production of engineered migrasomes by overexpressing Tspan4 in cells Tspan4 was a key protein for migrasome formation. To test whether Tspan4 could promote the formation of engineered migrasomes, stepwise hypotonic stimulation was performed on NRK cells overexpressing only mCherry-Kras or overexpressing both Tspan4-GFP and mCherry-Kras. After incubating NRK cells in KDPBS containing 2 μM latrunculin A for 10 min, stepwise hypotonic stimulation was performed in three consecutive steps by decreasing the salt concentration by 1 / 6 every 2 min, and then the formation of engineered migrasomes was observed by differential interference contrast microscopy. The results after stepwise hypotonic treatment are shown in Fig. 6a, and the statistical results of the number of engineered migrasomes produced per cell are shown in Fig. 6b.

[0368] Results showed that overexpression of Tspan4 significantly increased the number of engineered migrasomes.

[0369] Example 5. Production of engineered migrasomes by rapid cell detachment using temperature-sensitive coatings on culture dishes MGC803-T4-GFP cells were cultured on a temperature-sensitive culture dish, and after cytoskeleton disruption treatment, they were either hypotonic or not treated at room temperature or 37°C. The culture dish was left at room temperature for 45 minutes. More than 80% of the cells detached from the bottom of the culture and formed migrasomes, and some of them were detached from the bottom of the dish together with the cells (see Figure 7). The supernatant was collected and pipetted to collect the remaining cells and migrasomes.

[0370] Example 6. Production of engineered migrasomes in various cell lines To test whether engineered migrasomes could be produced under induction in cell lines of different species and genetic backgrounds, three different rodent cell lines (including normal rat kidney (NRK) cells, a mouse breast cancer cell line (4T1), and a mouse colon cancer cell line (MC38)), two commonly used human embryonic kidney cell lines / lines (HEK-293T and HEK-293FT), and three different human cell lines (human gastric carcinoma MGC-803 cells, human T lymphoma Jurkat cells, and human dermal fibroblast BJ cells), all of which overexpress Tspan4, were subjected to hypotonic induction. NRK cells were incubated for 10 min in K-DPBS containing 2 μM latrunculin A, followed by three consecutive stepwise hypotonic stimulations in which the salt concentration was decreased by 1 / 6 every 2 min. 4T1 cells were incubated in K-DPBS containing 2 μM latrunculin A for 20 min, followed by three consecutive steps of hypotonic stimulation with a quarter decrease in salt concentration every 2 min. MC38 cells were incubated in K-DPBS containing 2 μM latrunculin A for 45 min, followed by three consecutive steps of hypotonic stimulation with a quarter decrease in salt concentration every 2 min. The results are shown in Figure 8. It was found that vesicular structures were produced in the different cell lines.

[0371] The above-mentioned hypotonic treated cell lines were further stained with tetramethylrhodamine-labeled WGA, a migrasome-specific probe, and then observed by laser confocal microscopy. The results were shown in Figure 8b. Human cell lines (human embryonic kidney cells (HEK293T and HEK293FT, Figure 8c), human gastric cancer cells (MGC803), human skin fibroblasts (BJ), and human peripheral blood leukemia T cells (Jurkat), Figure 8d) were also tested. It was found that engineered migrasomes could be generated by the methods of Examples 1-5. The results showed that the vesicular structures produced in the eight cell lines under induction were stained by the migrasome probe WGA, indicating the production of engineered migrasomes.

[0372] The above results demonstrated that the methods of Examples 1-5 were capable of producing engineered migrasomes in different cell lines.

[0373] Example 7 Isolation, purification, and characterization of engineered migrasomes (Figures 9a-b) a. Production of engineered migrasomes by stimulating adherent cells I. Coating of culture flasks and spreading of cells 2 μg / ml human fibronectin was prepared using PBS and used to coat the bottom of a culture flask at 37° C. for 1 hour. Then, 1×10 7 Cells were spread at a density of cells / T175 culture flask.

[0374] II. Directed Production of Engineered Migrasomes 1. After culturing the cells for 14 to 16 hours, the culture medium was discarded and the cells were washed once with PBS. 2. K-DPBS containing 2 μM latrunculin A was added and the cells were incubated at 37°C (specific incubation times were adjusted depending on the sensitivity of the cell line to latrunculin A, e.g., 10 min for treatment of NRK cells and 45-60 min for treatment of MC38 cells. After treatment was completed, the cells should be in a wrinkled state with many meshwork structures similar to retraction fibers around the cell body). 3. The culture flask was placed on a horizontal shaker in a cell culture incubator with a rotation speed of 40 rpm, and water was added every 3 minutes for a total of three operations (the volume of water added at each step was determined by the hypotonic induction gradient and the initial volume of liquid in the culture flask. The hypotonic induction gradient differs depending on the cell line. For MC38 cells, the salt concentration was reduced by 1 / 4 at each step, the initial volume was 15 ml, and the volumes of water added three times were 5 ml, 6.5 ml, and 8.5 ml, respectively. For NRK cells, the initial volume was 15 ml, and the volumes of water added three times were 3 ml, 3.6 ml, and 4.4 ml). 4. The rotation speed was adjusted to 60 rpm and the mixture was shaken for 5 minutes.

[0375] b. Suspension cells were stimulated to produce engineered migrasomes. The cells (the number of which depends on the cell line) were removed, washed once with PBS and the supernatant was discarded.

[0376] The cells were resuspended in the culture flask by adding K-DPBS containing 2 μM latrunculin A, which was then placed in a horizontal shaker and incubated at a rotation speed of 40 rpm (times differed depending on the cell line).

[0377] Sterile water was added to the culture flasks to reduce osmolality (at different rates depending on the cell line).

[0378] The rotation speed was adjusted to 60 rpm and the mixture was shaken for 5 minutes.

[0379] To test whether engineered migrasomes could be produced in cell lines in suspension by induction, hypotonic induction was performed on two different rodent cell lines overexpressing Tspan4: normal rat kidney cells (NRK) and a mouse colon carcinoma cell line (MC38). The results are shown in Figure 9a and Figure 9b. Vesicle structures were produced in both cell lines in suspension, and Western blotting showed that vesicles purified from both cell lines showed enrichment of membrane proteins and lack of intracellular material characteristic of engineered migrasomes.

[0380] III. Isolation and purification of engineered migrasomes (Figure 10) A. Methods for purifying engineered migrasomes produced by adherent cells 1. The supernatant was discarded and the cells were washed twice with hypotonic KDPBS (h-KDPBS, whose salt concentration was similar to the salt concentration in the solution system when hypotonic induction was completed. For MC38 cells, h-KDPBS was 40% KDPBS. For NRK cells, h-KDPBS was 60% KDPBS). 2. h-KDPBS containing 1 mg / ml BSA (h-KDPBS-BSA) was added, and the mixture was shaken at 130 rpm for 3 minutes. 3. The supernatant was collected in a 50 ml centrifuge tube. 4. Add h-KDPBS-BSA, gently pipette up and down the bottom of the culture flask, and combine the collected liquid with the supernatant from step 3. 5. Centrifuge at 300 x g for 10 minutes at 4°C and retain the supernatant. 6. Centrifuge at 500 x g for 10 minutes at 4°C and retain the supernatant. 7. The supernatant was filtered into a 50 ml low-adsorption tube using a parylene filter membrane with a pore size of 8 μm. 8. Centrifugation was carried out at 4°C and 17,000 x g for 45 to 60 minutes, and the supernatant was discarded. 9. The pellet was resuspended in h-KDPBS-BSA and transferred to an EP tube (centrifuge tube 1) and an equal volume of PBS-BSA was added. At this point, a small amount of liquid (approximately 1 / 50 of the total volume) was taken and placed in another centrifuge tube (centrifuge tube 2) for protein concentration measurement. 10. Centrifugation was performed at 17,000 × g for 15–20 min at 4 °C, the supernatant was discarded, PBS was added, and the pellet was resuspended before injection to obtain engineered migrasomes resuspended in PBS.

[0381] b. Methods for purifying engineered migrasomes produced by suspension cells 1. The supernatant was collected and placed in a 15 ml centrifuge tube, then gently pipetted. 5. Centrifuge at 300 x g for 10 minutes at 4°C and retain the supernatant. 6. Centrifuge at 500 x g for 10 minutes at 4°C and retain the supernatant. 7. The supernatant was filtered into a low-adsorption tube using a parylene filter membrane with a pore size of 8 μm. 8. Centrifugation was carried out at 4°C and 17,000 x g for 45 to 60 minutes, and the supernatant was discarded. 9. The pellet was resuspended in PBS and transferred to an EP tube to obtain engineered migrasomes resuspended in PBS.

[0382] IV. Characterization of Engineered Migrasomes 1. Total Protein Determination The liquid in tube 2 was centrifuged at 17000×g for 5 min at 4° C. The supernatant was discarded, and then the pellet was washed once with PBS and the supernatant was discarded. The pellet was dissolved in 30 μl of 2% SDS. The resulting sample was boiled in a metal bath at 95° C. Protein concentration was determined by the BCA method to convert the total amount of protein in tube 1, and the corresponding resuspension volume was converted according to the injection dose.

[0383] 2. Morphological Observation 1 μl of engineered migrasome sample obtained from step III was diluted to 10 μl (WGA dye was added to the diluent at a ratio of 1:500 to 1:1000 to observe the vesicle morphology and detachment on the membrane surface), dropped onto the confocal capsule pre-coated with 10 μg / ml fibronectin, left at room temperature for more than 1 h, and observed under a laser confocal microscope. The results are shown in Figure 11a.

[0384] Furthermore, the engineered migrasomes obtained in step III were observed by negative staining transmission electron microscopy and cryo-electron microscopy, and the results are shown in Figure 11b and Figure 11c, respectively.

[0385] 3. Flow Cytometry Dilute 1 μl of the liquid from step III-9 or 10 to 100 μl. If the vesicles showed two-color fluorescence, they could be diluted directly in PBS. If the vesicles showed only single-color fluorescence, they could be stained with 1:500 WGA dye to improve the clustering effect.

[0386] 4. Western Blotting In step III-1, a small amount of liquid was collected from the supernatant, centrifuged at 100×g, and the pellet was dissolved in 2% SDS to prepare a cell sample. The sample obtained in step IV-1 was used as the engineered migrasome sample. The cell sample and engineered migrasome (eMig) sample were loaded with equal protein content for Western blotting to detect the nucleus (histone H3), mitochondria (Tim23), endoplasmic reticulum (calnexin), lysosome (Lamp2), cytoplasm (GAPDH), cell membrane (Na +-K + Classical markers of various organelles were detected, including Tspan4-GFP (GFP), plasma membrane focal adhesions (integrin α5), and Tspan4-GFP (Tspan4-ATPase). The results are shown in Figure 12.

[0387] Results showed that the isolated and purified engineered migrasomes express Tspan4, integrin a5, and Na + -K + -ATPase and showed little or no contamination from intracellular organelles and soluble proteins.

[0388] 5. Permeability Assessment The isolated and purified engineered migrasomes were dropped into the confocal capsules, and Cy5 (a fluorescent dye that cannot pass through intact membranes) and dextran-TMR (Dex-TMR) were added to the buffer to show the permeability of the vesicles. Long-term photography was performed on the droplets using a laser confocal microscope, and the results are shown in Figure 13a. It could be observed that the engineered migrasomes were almost completely permeable to Cy5 (MW<1 kDa) at room temperature from the very beginning, and showed slow permeability to dextran-TMR (MW=40 kDa) with a larger molecular weight. The permeability ratio to dextran-TMR after storing the engineered migrasomes at room temperature for 1.5 h, 6 h, 12 h, 24 h, and 48 h was shown in the statistical results in Figure 13b.

[0389] 6. Stability Assessment To examine the stability of engineered migrasomes at room temperature, isolated and purified engineered migrasomes were dropped into confocal capsules and observed morphologically on days 0, 1, 2, 3, 5, and 7, respectively, and the results were shown in Figure 14a. Six samples kept in parallel were subjected to Western blotting to detect loaded OVA and mCherry (Figure 14b) on days 0, 3, 7, and 14, and they were used to immunize mice to detect the concentration of OVA-specific antibodies in serum (Figure 14c).

[0390] The results showed that the engineered migrasomes had intact vesicle morphology, stable protein expression, and essentially no change in immunogenicity as a vaccine during storage at room temperature for 7 to 14 days, indicating that the engineered migrasomes were highly stable.

[0391] 7. Effect of cholesterol on the stability of engineered migrasomes It was previously reported that cholesterol is essential for the formation of migrasomes (Huang Y, Zucker B, Zhang S, Elias S, Zhu Y, Chen H, Ding T, Li Y, Sun Y, Lou J, Kozlov MM, Yu L. Migrasome formation was mediated by assembly of micron-scale tetraspanin macrodomains. Nat Cell Biol. 2019 Aug; 21(8): 991-1002). To investigate the effect of cholesterol on the formation of engineered migrasomes, the isolated and purified engineered migrasomes were treated with methyl-β-cyclodextrin (MβCD), which can selectively extract cholesterol from the plasma membrane. The cholesterol extraction reagent MβCD (10 mM) was added to the droplets and examined by laser confocal microscopy, and the results were shown in Figure 15. It was found that most of the engineered migrasomes were severely deformed and damaged within 10 min, indicating that cholesterol has a significant effect on the stability of engineered migrasomes.

[0392] Drug loading of engineered migrasomes Example 8. Loading of membrane proteins into engineered migrasomes During the production of engineered migrasomes, a portion of the cell membrane could be converted into the migrasome membrane, and thus the delivery of membrane proteins could be achieved by directly introducing a plasmid encoding the gene of interest and Tspan4 into the production cells (Figure 16a). Overexpression of Tspan4 in combination with other steps in the production of engineered migrasomes can significantly increase the productivity of engineered migrasomes, and the overexpressed membrane proteins are enriched on the resulting engineered migrasomes, thus achieving the loading of membrane proteins into engineered migrasomes. Membrane proteins that can be loaded include various cell receptors (e.g., various GPCRs, PD-1, VEGFR, etc.), extracellular enzymes (e.g., CD36 and CD73), ion channels, transporters, and various antigens (e.g., S-protein), etc.

[0393] As an example, we verified the loading of three typical plasma membrane proteins DAG1, Tgfbr1, and PDCD1, the membrane-associated protein Kras (Figure 17), and the spike (S) protein of SARS-CoV-2 (Figure 18) into engineered migrasomes.

[0394] For the membrane proteins DAG1, Tgfbr1, PDCD1, and Kras, plasmids containing Tspan4-GFP and the gene sequences of interest were transfected into producer NRK cells. To facilitate observation of the intracellular localization and expression of the proteins of interest, the gene fragments of interest were fused to an mCherry tag via a linker. The amino acid sequence and vector information for each fusion protein are shown below.

[0395] Tspan4-Linker-GFP (vector: pB-Hygro-GFP (vector map shown in FIG. 19), insertion sites BsrGI+BamHI): (SEQ ID NO: 1)

number

[0396] The amino acid sequence of Tspan4 is underlined. The amino acid sequence of GFP is shown in bold italics. The amino acid sequence between Tspan4 and GFP was a linker sequence (PG).

[0397] DAG1-Linker-mCherry (Vector: pmCherry-N1 (vector map shown in FIG. 20), Insertion sites: EcoRI+KpnI): (SEQ ID NO: 2)

number

[0398] The amino acid sequence of DAG1 is underlined. The amino acid sequence of mCherry is shown in bold italics. The amino acid sequence between DAG1 and mCherry was a linker sequence (GDPPVAT).

[0399] PDCD1-Linker-mCherry (vector: pB-Hygro-mCherry (vector map shown in FIG. 21), insertion sites: BsrGI+MluI): (SEQ ID NO: 3)

number

[0400] The amino acid sequence of PDCD1 is underlined. The amino acid sequence of mCherry is shown in bold italics. The amino acid sequence between PDCD1 and mCherry was a linker sequence (TVPRARDPPVAT).

[0401] Tgfbr1-Linker-mCherry (Vector: pmCherry-N1 (vector map shown in FIG. 20), Insertion sites: EcoRI+KpnI): (SEQ ID NO: 4)

number

[0402] The amino acid sequence of Tgfbr1 is underlined. The amino acid sequence of mCherry is shown in bold italics. The amino acid sequence between Tgfbr1 and mCherry was a linker sequence (TVPRARDPPVAT).

[0403] mCherry-Linker-Kras (vector: pB-Hygro-mCherry (vector map shown in FIG. 21), insertion sites: BsrGI+MluI): (SEQ ID NO: 5)

number

[0404] The amino acid sequence of mCherry is underlined. The amino acid sequence of Kras is shown in bold italics. The amino acid sequence between mCherry and Kras was a linker sequence (SGLRSRG).

[0405] After transfection, cells were treated with antibiotics and screened for resistance encoded by the plasmid to establish cell lines stably expressing various mCherry-tagged membrane proteins. The cell lines were then induced to produce engineered migrasomes reloaded with the corresponding membrane proteins using the hypotonic treatment conditions of NRK cells in Example 5, and then observed by laser confocal microscopy. The results showed that all four membrane proteins of interest were accurately localized on the engineered migrasomes (Figure 17), indicating that membrane proteins can be incorporated onto the engineered migrasomes.

[0406] For S protein, a plasmid containing Tspan4-GFP and the gene sequence of interest was transfected into MC38 cells, a producer cell. To facilitate observation of the intracellular localization and expression of the protein of interest, an mCherry tag was fused to the gene fragment of interest. After transfection, the cells were treated with antibiotics and screened for resistance encoded by the plasmid to establish a cell line stably expressing mCherry-tagged S protein. The cell line was then induced to produce engineered migrasomes loaded with S protein using the hypotonic treatment conditions of MC38 cells in Example 5, and then observed by laser confocal microscopy. The results showed that the S protein of interest was precisely localized on the engineered migrasome (Figure 18), indicating that the S protein could be effectively incorporated onto the engineered migrasome.

[0407] Example 9 Loading of soluble proteins into engineered migrasomes Because engineered migrasomes are permeable, they are unlikely to be used for the direct delivery of cytosolic soluble proteins. To achieve delivery of soluble proteins, permeation of soluble proteins could be prevented by having the producing cells express a fusion protein of the protein of interest with a membrane protein to anchor the soluble protein on the membrane (Figure 16a and Figure 16b). For example, the N-terminus of the membrane protein syntaxin 2 (STX2) could be modified to remove its intracellular terminal function, resulting in a truncated t-STX2. A soluble protein was then attached to the extracellular C-terminus of t-STX2 to form a soluble protein-t-STX2 fusion protein (Figure 16b), and the soluble protein was expressed as an artificial plasma membrane-localized fusion protein. The topology of t-STX2 itself allows the soluble protein of interest to end up dangling outside the cell membrane, making it easier for the protein to be recognized by the immune system as an intact antigen, for example.

[0408] In addition to STX2, various other membrane proteins, such as tetraspanin-4, CD81, CD9, CD63, PDGFR, Lamp2b, etc., are frequently used as membrane-anchored proteins.

[0409] As an example, we verified the loading of the soluble protein OVA into the engineered migrasome. Plasmids containing sequences encoding Tspan4-GFP and t-STX2-OVA-mCherry were transfected into producer MC38 cells. The amino acid sequence of the fusion protein of t-STX2 and OVA and the vector information are shown below.

[0410] t-STX2-linker-OVA-linker-mCherry (vector pmCherry-N1 (vector map shown in FIG. 20), insertion sites: HindIII+BamHI): (SEQ ID NO: 6)

number

[0411] The amino acid sequence of t-STX2 is shown in bold, the amino acid sequence of OVA is underlined, and the amino acid sequence of mCherry is shown in bold italics.

[0412] After transfection, cells were treated with antibiotics and screened for resistance encoded by the plasmid to establish cell lines stably expressing mCherry-tagged t-STX2-OVA fusion protein. The cell lines were then induced to produce engineered migrasomes loaded with t-STX2-OVA fusion protein using the hypotonic treatment conditions of MC38 cells in Example 5, and then observed by laser confocal microscopy, with the results shown in Figure 22.

[0413] The results showed that the t-STX2-OVA fusion protein was accurately localized on the engineered migrasomes, indicating that the soluble protein OVA was successfully loaded onto the engineered migrasomes.

[0414] Example 10 Loading engineered migrasomes with other molecules of interest Loading of engineered migrasomes with small molecule drugs, small nucleic acid drugs, peptide fragments, or other molecules of interest could be achieved by modifying the molecules of interest and the producing cells with antigen-antibody, receptor-ligand, and biotin-avidin binding systems (Figure 16a). For example, the loading of a desired molecule into engineered migrasomes could be achieved by using the receptor-ligand interaction between HaloTag and its artificial ligand (Los, GV, Encell, LP, McDougall, MG, Hartzell, DD, Karassina, N., Zimprich, C., Wood, MG, Learish, R., Ohana, RF, Urh, M., Simpson, D., Mendez, J., Zimmerman, K., Otto, P., Vidugiris, G., Zhu, J., Darzins, A., Klaubert, DH, Bulleit, RF, & Wood, KV (2008). HaloTag: a novel protein labeling technology for cell imaging and protein analysis. ACS chemical biology, 3 (6), 373-382.). First, a plasmid of the fusion protein Tspan4-HaloTag encoding the membrane protein Tspan4 and the receptor protein HaloTag was constructed. The plasmid was then transfected into the production cells for engineered migrasomes to modify the production cells. The modified production cells were induced to produce engineered migrasomes, and after isolation and purification, the engineered migrasomes contained the receptor protein HaloTag on their membranes. The molecule of interest was modified by conjugating it to the ligand of HaloTag to form a molecule of interest-ligand conjugate. The molecule of interest-ligand conjugate was then co-incubated in vitro with the engineered migrasomes containing HaloTag in their membranes, and the molecule of interest was immobilized in the membrane and / or inside of the engineered migrasomes by the interaction of HaloTag with its ligand. The covalent conjugation of HaloTag to its ligand was specific, efficient, and irreversible.

[0415] In addition to Tspan4, other membrane proteins, such as those described elsewhere herein, could also be used as membrane anchoring proteins for loading of molecules of interest into engineered migrasomes. In addition to HaloTag and its ligands, other antigen-antibody, receptor-ligand, biotin-avidin, or other binding systems, such as the CP05-CD63 binding system, could also be used for loading of molecules of interest into engineered migrasomes (X. Gao, N. Ran, X. Dong, B. Zuo, R. Yang, Q. Zhou, HM Moulton, Y. Seow, H. Yin, Anchor peptide captures, targets, and cargos exosomes of diverse origins for diagnostics and therapy, Sci. Transl. Med. 10 (2018)), where the receptor CD63 was first loaded onto the membrane of engineered migrasomes, and then the molecule of interest-CP05 conjugate was loaded onto the membrane of engineered migrasomes containing CD63 by binding of CD63 to its ligand CP05. If antigen-antibody, receptor-ligand, or biotin-avidin binding systems are chosen, receptors that have multiple natural ligands in vivo (eg, PD-1) can be maximally avoided.

[0416] To achieve the proof-of-concept of this loading method, a plasmid containing a sequence encoding Tspan4-HaloTag-GFP was transfected into producer NRK cells, and a plasmid containing a sequence encoding Tspan4-GFP was transfected as a control. The amino acid sequence of the fusion protein of Tspan4 and HaloTag and the vector information are shown below.

[0417] Tspan4-Linker-GFP-Linker-Halo (vector: pB-Hygro-GFP (vector map shown in Figure 19), insertion sites: BsrGI+MluI): (SEQ ID NO: 7)

number

[0418] The amino acid sequence of Tspan4 is shown in bold. The amino acid sequence of GFP is underlined. The amino acid sequence of Halo is shown in bold italics.

[0419] After transfection, cells were treated with antibiotics and screened for resistance encoded by the plasmid to establish a cell line with stable expression. The cell line was then induced to produce engineered migrasomes using the hypotonic treatment conditions of NRK cells in Example 5. Fluorescent HaloTag ligand-TMR dye was added to the engineered migrasomes, then incubated at room temperature for 15 minutes, washed twice with dye-free buffer, dropped into confocal capsules, left at room temperature for 5 hours, and then observed under a laser confocal microscope, and the results are shown in Figure 23.

[0420] The results showed that HaloTag ligand-TMR and Tspan4-HaloTag-GFP were colocalized on engineered migrasomes, indicating that the interaction between HaloTag and its ligand allows loading of molecules of interest onto engineered migrasomes in an efficient, specific, and irreversible manner.

[0421] In addition to loading engineered migrasomes by antigen-antibody, receptor-ligand, or biotin-avidin conjugation as described above, small molecule nucleic acid drugs could also be loaded onto the membrane of engineered migrasomes by various other modification methods. For example, by conjugating chemically modified siRNA or antisense oligonucleotides (ASOs) to cholesterol, small molecule nucleic acid drugs could be loaded onto the membrane of engineered migrasomes due to the affinity between cholesterol and cell membranes (SS Yerneni, S. Lathwal, P. Shrestha, H. Shirwan, K. Matyjaszewski, L. Weiss, ESYolcu, PGCampbell, SRDas, Rapid on-demand extracellular vesicle augmentation with versatile oligonucleotide tethers, ACS Nano 13(2019)10555-10565). This approach was a rapid and inexpensive loading approach without further modification to migrasomes. It was also possible to immobilize siRNA conjugates on membranes (T. Tian, ​​HX Zhang, CP He, S. Fan, YL Zhu, C. Qi, NP Huang, ZD Xiao, ZH Lu, BA Tannous, J. Gao, Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy, Biomaterials 150 (2018) 137-149). This approach involved conjugating siRNA to a peptide fragment and then conjugating the peptide fragment to a membrane by click chemistry.

[0422] Loading of mRNA drugs into engineered migrasomes could be achieved by mRNA-binding proteins. Commonly used mRNA-binding proteins include L7Ae (Kojima, R., Bojar, D., Rizzi, G., Hamri, GC, El-Baba, MD, Saxena, P., Auslander, S., Tan, KR, & Fussenegger, M. (2018). Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson's disease treatment. Nature communications, 9(1), 1305; Zhitnyuk, Y., Gee, P., Lung, M., Sasakawa, N., Xu, H., Saito, H., & Hotta, A. (2018). Efficient mRNA delivery system utilizing chimeric VSVG-L7Ae virus-like particles. Biochemical and biophysical research communications, 505(4), 1097-1102) and MS2BP (Prel, A., Caval, V., Gayon, R., Ravassard, P., Duthoit, C., Payen, E., Mauche-Chretien, L., Crene guy, A., Nguyen, TH, Martin, N., Piver, E., Sevrain, R., Lamouroux, L., Leboulch, P., Deschaseaux, F., Bouille, P., Sensebe, L., & Pages, JC, Highly Contains efficient in vitro and in vivo delivery of functional RNAs using new versatile MS2-chimeric retrovirus-like particles,Mol.Ther.-Meth.Clin.Dev.2(2015),15039).First, a plasmid encoding a membrane protein-mRNA binding protein fusion protein, such as Tspan4-L7Ae or Tspan4-MS2, was constructed. Then, an mRNA expression plasmid containing a protein binding site was constructed, in which the protein binding site of L7Ae was the C / D Box and the protein binding site of MS2BP was the MS2 stem loop (MS2SL). The fusion protein plasmid and the mRNA plasmid were then co-introduced into the production cells to induce the production cells to produce engineered migrasomes, and after isolation and purification, the migrasomes contained the target mRNA molecule on their membranes.

[0423] Example 11: Induction of immune responses in mice by engineered migrasomes loaded with SARS-CoV-2 spike protein The experimental procedure is shown in Figure 24a. The experimental animals were 8-week-old female mice of the C57BL / 6 strain, with 5 mice in each group. Specifically, each group was as follows: I. 50 μg of S1 recombinant protein (SinoBiological) + aluminum adjuvant (thermo scientific), intraperitoneal injection (ip) II. 10 μg of S1 recombinant protein, intravenous injection (iv) III. Engineered migrasomes with 20 μg total protein and expression of Tspan4-GFP only (NC-eMig), intravenous tail injection, as a negative control IV. Engineered migrasomes with 20 μg total protein and co-expression of Tspan4-GFP and S protein-mCherry P (S-eMig), intravenous tail vein injection

[0424] The S-eMig group was semi-quantitatively analyzed for S1 protein levels using Western blotting (Figure 24b). The first six lanes from the left show 1 ng, 2 ng, 5 ng, 10 ng, 20 ng, and 50 ng of S1 recombinant protein, respectively, and lanes 7-10 show NC-eMig or S-eMig with a total protein level of 1 μg each (eMig-1 and eMig-2 represent samples from two independent experiments). By comparing the intensity of each lane band, it could be calculated that approximately 100 ng of S1 protein was present in one dose of S-eMig (20 μg), which is much lower than the amount of S1 recombinant protein (50 μg) used in the aluminum adjuvant group.

[0425] Mice were immunized once on day 0 and sacrificed on day 14 to collect peripheral blood. The concentration of S protein-specific IgG antibodies in serum was detected by ELISA, and the results were shown in Figure 24c. It was found that neither the S1 protein group (group II) nor the NC-eMig negative control group (group III) could promote antibody production with a single injection, while both the S1 protein + aluminum adjuvant group (group I) and the S-eMig group (group IV) could effectively promote antibody production, and the immunization effects of both were almost similar. This indicated that compared with conventional immunization using adjuvants and immunogenic proteins, engineered migrasomes are a more efficient delivery vector that can induce similar antibody responses using a small amount of protein without adjuvants and thus effectively promote immune responses.

[0426] Comparison of engineered migrasomes with known extracellular vesicles

[0427] Example 12 Comparison of engineered and natural migrasomes For multifaceted comparison, we produced and purified control migrasomes (see Ma et al., Cell Res. 2015 for production and purification procedures) and engineered migrasomes (see Figure 9 for production and purification procedures) of the same cellular origin.

[0428] Tspan4-GFP overexpressing NRK cells were hypotonically treated, then fixed with 2.5% glutaraldehyde, and observed by scanning electron microscopy (Fig. 25a). 4D photography of the production of engineered migrasomes by Tspan4-GFP overexpressing NRK cells was performed by spinning disk confocal microscopy. During hypotonic treatment, it was observed that the cell body swelled, the basal surface retracted, and numerous filamentous structures were produced, and engineered migrasomes grew on these filamentous structures (Fig. 25b).

[0429] Natural migrasomes were due to the movement of the cell center point and were attached to retraction fibers located only behind the moving cell, and the number of these migrasomes was small (Figure 26a). Engineered migrasomes were due to the relative movement of the cell membrane induced by various methods and were attached to retraction fibers that could be distributed in all directions of the cell, and the number of migrasomes on each retraction fiber and in a single cell was significantly higher than that of control migrasomes (Figure 26b). Tspan4-GFP overexpressing NRK cells were stained with tetramethylrhodamine-labeled WGA to clearly show the difference between control migrasomes (upper panel of Figure 26c) and engineered migrasomes (lower panel of Figure 26c). Natural migrasomes had various numbers of secretory vesicles inside under electron microscopy (Figure 26d, from Ma et al, Cell Res. 2015), while engineered migrasomes had limited or absent contents under electron microscopy (Figure 26e). Mass spectrometry performed on engineered and control migrasomes (also called nonhypotonic or native migrasomes) of the same cellular origin showed that nearly 4000 proteins were absent in engineered migrasomes compared to native migrasomes (Figure 26f), although some of the proteins were significantly enriched in native migrasomes compared to the cell body (Figure 26g).Furthermore, engineered migrasomes showed expression of 1350 proteins not present in natural migrasomes, and more proteins such as ERM family member proteins (including ezrin) and Fxyd5 and Atp1β1 proteins were found to be expressed on the membrane of some engineered migrasomes (Figure 26h) (Reference: Ma L, Li Y, Peng J, Wu D, Zhao X, Cui Y, Chen L, Yan X, Du Y, Yu L. Discovery of the migrasome, an organelle mediating release of cytoplasmic contents during cell migration. Cell Res. 2015 Jan;25(1):24-38. doi:10.1038 / cr.2014.135.).

[0430] Example 13 Differences between engineered migrasomes and other hypotonic vesicles Under scanning electron microscopy, the engineered migrasomes produced by NRK cells (Figure 25a) were found to be different from the reported hypotonic vesicles (Figure 25c). Their main differences in process and characteristics were as follows: 1) The engineered migrasomes were produced on the fibers surrounding the cells, not on the top surface of the cells as revealed by the experimental data of Cohen et al. 2) Engineered migrasomes had micron-scale sizes and rarely exceeded 5 μm in diameter, whereas vesicles produced by Cohen et al. using hypotonicity could be as large as 20 μm. 3) Hypotonic induction for engineered migrasomes was a gentle stepwise reduction process (final osmolality was 40% or higher in some current cell lines), whereas a vigorous treatment with 5% PBS was used by Cohen et al., who used a 118% hypertonic buffer during vesicle formation (References: Cohen S, Ushiro H, Stoscheck C, Chinkers MA native 170 000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J Biol Chem 257:1523-1531.).

[0431] Example 14 Differences between engineered migrasomes and small extracellular vesicles / exosomes Although migrasomes and exosomes were both extracellular vesicles, they differed in their production mechanism, vesicle size (exosomes are generally 50-150 nm), or other characteristics. Small extracellular vesicles (sEVs) / exosomes (see Figure 27a for production and purification procedures) and engineered migrasomes (see Figure 9 for production and purification procedures) of the same cellular origin were produced, purified, and compared in various aspects. NTA detection (Figure 27b) and transmission electron microscope (TEM) observation (Figure 27c) of purified exosomes demonstrated that the size and morphology of exosomes were consistent with those described in the literature. Furthermore, Western blotting demonstrated that purified exosomes were enriched with recognized extracellular vesicles / exosome markers such as tsg101, Alix, CD63, and CD81, but these small extracellular vesicles / exosome markers were not enriched in engineered migrasomes. At the same time, the engineered migrasomes were enriched with more migrasome markers, such as sodium / potassium ATPase and Lamp2 (Figure 27d), indicating that migrasomes and exosomes of the same cellular origin were efficiently produced and purified but with significant differences in protein composition and markers.

[0432] Methods for Producing Engineered Migrasomes: Tspan4-GFP-overexpressing MC-38 cells were spread and cultured on fibronectin-treated cell culture dishes 1 day prior.

[0433] On the day of the experiment, the supernatant was discarded and the cells were washed with 40% KDPBS. h-KDPBS containing 1 mg / ml BSA (h-KDPBS-BSA) was added and the resulting mixture was shaken at 130 rpm for 3 min. The supernatant was collected. h-KDPBS-BSA was added, the bottom of the culture flask was pipetted, and the collected liquid was combined with the supernatant from the previous step. Centrifugation was performed at 4 °C and 300 × g for 10 min, and the supernatant was retained. Centrifugation was performed at 4 °C and 500 × g for 10 min, and the supernatant was retained. The supernatant was filtered into a 50 ml low-adsorption tube using a parylene filter membrane with a pore size of 8 μm. Centrifugation was performed at 4 °C and 17000 × g for 45 to 60 min, and the supernatant was discarded. The pellet was resuspended in h-KDPBS-BSA and transferred to an EP tube (centrifuge tube 1), to which an equal volume of PBS-BSA was added. Here, 1 / 50 of the total volume of the obtained material was transferred to another centrifuge tube (centrifuge tube 2) for measurement of protein concentration. Centrifugation was performed at 17,000 × g at 4 °C for 15-20 min, the supernatant was discarded, PBS was added, and the pellet was resuspended before injection to obtain engineered migrasomes resuspended in PBS.

[0434] Production and purification of small extracellular vesicles MC-38 cell line overexpressing mouse Tspan4-GFP protein was seeded at approximately 20% cell confluency and cultured for 72 hours. The culture medium was collected and centrifuged at 4,000×rcf for 10 minutes to remove cell bodies, and the supernatant was collected. The supernatant was filtered through a 0.45 μm filter membrane. The filtered supernatant was concentrated in a 70 kD ultrafiltration tube. 1 mM MgCl2 and 20 U / mL benzonase were added to the concentrated supernatant and treated at room temperature overnight. The resultant was filtered through a 0.22 μm filter membrane. The filtered liquid was centrifuged in an ultracentrifuge at 140,000×g at 4°C for 1 hour. The supernatant was discarded, and the pellet was collected and resuspended in PBS. The resuspended pellet was mixed with 60% iodixanol and added to the bottom of the ultracentrifuge tube. 9 mL of 30% iodixanol, 5 mL of 23% iodixanol, and 6 mL of 18% iodixanol were added sequentially to the ultracentrifuge tube. The resultant was centrifuged at 150,000 × g for 16 hours, and each density gradient interphase component (4 components in total, F1 to F4) was gently pipetted and collected. The collected exosome components were mixed with 30 mL of PBS and centrifuged at 16,000 × g for 1 hour, and the supernatant was retained. The supernatant was filtered through a 0.2 μm filter membrane and then centrifuged at 150,000 × g for 2 hours at 4 °C, and the pellet was collected at 1 × 10 13 The cells were resuspended at 2000x1000particles / mL and stored frozen for later use.

[0435] Based on the production and purification of small extracellular vesicles / exosomes and engineered migrasomes from the same cell line, the applicant found that the unit yield of engineered migrasomes was much higher than that of small extracellular vesicles, and the production rate was significantly increased because there was no need for purification such as ultracentrifugation, density gradient ultracentrifugation, etc. When cultured using an equivalent amount of cells, the yield of engineered migrasomes was about 35 times that of small extracellular vesicles / exosomes (Figure 27e).

[0436] At the same time, 5 minutes after tail vein injection of small extracellular vesicles and engineered migrasomes with equal amounts of dye in C57BL / 6 mice, the accumulation of engineered migrasomes and small extracellular vesicles in various organs was similar. With increasing time, 4 and 24 hours after injection, the accumulation of engineered migrasomes in liver, spleen, and lungs was significantly increased compared to small extracellular vesicles, which also indicated the difference between them in metabolism and tissue accumulation in vivo, and the delivery efficiency of engineered migrasomes was better when equal amounts of dye were used (Figure 27f).

[0437] Mass spectrometry was performed on small extracellular vesicles / exosomes and engineered migrasomes from the same cell line, and PCA analysis showed that the three engineered migrasome samples were similar but significantly different from the three small extracellular vesicles / exosomes (Figure 28a). The signaling pathway analysis heat map (Figure 28b) and the 10 most enriched proteins (Figure 28c) showed significant differences between small extracellular vesicles / exosomes and engineered migrasomes.

[0438] The above detailed description has been provided by way of illustration and example, and is not intended to limit the scope of the appended claims. Various modifications of the embodiments recited hereinbefore will be apparent to those skilled in the art and should be retained within the scope of the appended claims and their equivalents.

Claims

1. A method for producing migrasomes, comprising relatively moving cells to produce migrasomes derived from the cells.

2. The method of claim 1, further comprising isolating the migrasome produced by the cell.

3. The method according to any one of claims 1 to 2, comprising subjecting the cells to a hypotonic treatment.

4. The method of claim 3 , wherein the hypotonic treatment comprises placing the cells in a hypotonic buffer.

5. 5. The method of claim 3, wherein the hypotonic treatment comprises placing the cells in a buffer and reducing the osmolarity of the buffer to make it a hypotonic buffer.

6. The method of claim 5, wherein the reduction in osmolarity comprises a linear reduction and / or a stepwise reduction.

7. The method according to any one of claims 5 to 6, wherein the osmolarity of the hypotonic buffer is less than about 305 mOsmol / L.

8. The method according to any one of claims 5 to 7, wherein the osmolarity of the hypotonic buffer is from about 10 mOsmol / L to about 274.5 mOsmol / L.

9. The method according to any one of claims 1 to 8, comprising disrupting the cytoskeleton of the cell.

10. The method of claim 9, wherein disrupting the cytoskeleton of the cell comprises contacting the cell with a cytoskeleton disrupting reagent.

11. The method of claim 10, wherein the cytoskeleton disrupting reagent comprises a microfilament and / or microtubule depolymerizing agent.

12. The method of any one of claims 10 to 11, wherein the cytoskeleton disrupting reagent comprises latrunculin A, latrunculin B, cytochalasin A, cytochalasin B, cytochalasin C, cytochalasin D, and / or cytochalasin E.

13. The method according to any one of claims 1 to 12, comprising inhibiting a cell volume regulatory function of the cell.

14. The method of claim 13, wherein inhibiting the cell volume regulatory function of the cell comprises reducing the number and / or function of volume regulatory proteins in the cell.

15. The method of claim 14 , wherein the volume-regulatory protein comprises a volume-regulatory ion channel and / or transporter.

16. 16. The method of claim 15, wherein the volume-regulating ion channel comprises a volume-regulating anion channel VRAC and / or a volume-regulating cation channel VRCC.

17. 17. The method of claim 16, wherein the volume-regulatory anion channel VRAC comprises SWELL1 or a functionally active fragment thereof.

18. The method of any one of claims 16 to 17, wherein the volume-regulatory cation channel VRCC comprises TRPV4, TRPM3, and / or a functionally active fragment thereof.

19. The method of any one of claims 15 to 18, wherein the transporter comprises a cotransporter.

20. The method of claim 19, wherein the cotransporter comprises KCC1, KCC3, and / or KCC4.

21. The method according to any one of claims 13 to 20, wherein inhibiting the cell volume regulatory function of the cell comprises placing the cell in a buffer capable of inhibiting the volume regulatory ability of the cell.

22. 22. The method of claim 21, wherein the buffer contains increased cations.

23. The cation is K + , Na + , Cs + , Li + , Ca 2+ , Mg 2+ , Ba 2+ , Mn 2 + , Fe 2 + , Ni 2 + , Zn 2 + , Al 3 + , Fe 3 + , C.H. 3 N.H. 3 + , C 2 H 5 N.H. 3 + , (CH 3 ) 2 N.H. 2 + , (C 2 H 5 ) 2 N.H. 2 + , (C 2 H 5 ) 3 N + , ammonium ions, and / or choline ions.

24. 22. The method of claim 21, wherein the buffer comprises increased anions.

25. The anion is Br - , Cl - , I - , F - , O.H. - , HCO 3 - , H 2 P.O. 4 - , NO 2 - , NO 3 - , C.N. - , H.P.O. 4 2- , CO 3 2- , S.O. 4 2- , and / or P.O. 4 3- 25. The method of claim 24, comprising:

26. The method of any one of claims 1 to 25, wherein the method comprises detaching the cells from the surface to which they are attached.

27. The method according to any one of claims 1 to 26, wherein the method comprises a relative movement between the cell membrane of the cell and the adherent surface.

28. The method of any one of claims 1 to 27, further comprising increasing the number and / or function of tetraspanin proteins, functional fragments thereof, and / or functional variants thereof in said cell.

29. 29. The method of claim 28, comprising overexpressing the tetraspanin protein, a functional fragment thereof, and / or a functional variant thereof in the cell.

30. The tetraspanin proteins are Tspan1, Tspan2, Tspan3, Tspan4, Tspan5, Tspan6, Tspan7, Tspan8, Tspan9, Tspan10, Tspan11, Tspan12, Tspan13, Tspan14, Tspan15, Tspan16, Tspan17, Tspan18, Tspan19, Tspan20 (UPK1B), Tspan21 (UPK1 30. The method of any one of claims 28 to 29, wherein the Tspan24 (CD151), Tspan25 (CD53), Tspan26 (CD37), Tspan27 (CD82), Tspan28 (CD81), Tspan29 (CD9), Tspan30 (CD63), Tspan31, Tspan32, and Tspan33.

31. 31. The method of any one of claims 1 to 30, further comprising reducing the size of the migrasomes.

32. 32. The method of claim 31, wherein reducing the size of the migrasomes comprises passing the migrasomes through a filter or an extruder.

33. 33. The method of claim 32, wherein the filter or extruder has a pore size of about 30 nm to about 10,000 nm.

34. 34. The method of any one of claims 31 to 33, wherein the size of the migrasomes is from about 50 nm to about 8000 nm.

35. The method of any one of claims 1 to 34, wherein the migrasomes are generated from retraction fibers of the cells.

36. The method according to any one of claims 1 to 35, wherein the membrane of said migrasome is enriched with sodium / potassium ATPase and / or functional fragments thereof.

37. The method according to any one of claims 1 to 36, wherein the membrane of said migrasomes is enriched with integrins and / or functional fragments thereof.

38. The method according to any one of claims 1 to 37, wherein the membrane of said migrasome is enriched with a tetraspanin protein, a functional variant thereof and / or a functional fragment thereof.

39. The method of any one of claims 1 to 38, wherein the membrane of the migrasome is enriched with cholesterol.

40. The method of any one of claims 1 to 39, wherein the migrasomes are enriched in membrane microdomains.

41. The method of any one of claims 1 to 40, wherein the migrasomes are produced in vitro or ex vivo.

42. 42. The method of any one of claims 1 to 41, wherein the content of said migrasomes is at least partially reduced or absent compared to native migrasomes produced by the corresponding cells.

43. 43. The method of claim 42, wherein the at least partially reduced content comprises intraluminal vesicles.

44. The method according to any one of claims 1 to 43, which is an in vitro method or an ex vivo method.

45. The method of any one of claims 1 to 44, wherein the cells are cells cultured in vitro.

46. The method according to any one of claims 1 to 45, wherein the cells are suspension cultured cells or adhesion cultured cells.

47. The method of any one of claims 1 to 46, wherein the cells comprise primary cells.

48. 48. The method of claim 47, wherein the primary cells comprise tissue cells derived from organisms including humans, monkeys, mice, rats, rabbits, chickens, and / or insects.

49. 49. The method of any one of claims 47 to 48, wherein the primary cells comprise liver cells, spleen cells, kidney cells, tissue macrophages, brain glial cells, osteoclasts, bone marrow cells, leukocytes, fibroblasts, and / or adipocytes.

50. 50. The method of claim 49, wherein the leukocytes comprise B cells, T cells, NK cells, dendritic cells, neutrophils, and / or macrophages.

51. The method of any one of claims 1 to 50, wherein the cell comprises a tumor cell.

52. 52. The method of claim 51, wherein the tumor cells comprise a tumor cell line, a patient-derived primary or restricted passage tumor cell, a tumor stromal cell, and / or a tumor organoid.

53. 53. The method of any one of claims 1 to 52, wherein the cells comprise CHO cells, CHO-K1 cells, HEK293 cells, HEK293T cells, HEK293FT cells, HEK293F cells, Vero cells, NRK cells, L929 cells, MC38 cells, 4T1 cells, DC2.4 cells, MGC803 cells, Jurkat cells, NK-92MI cells, BJ cells, and / or HepG2 cells.

54. The method of any one of claims 1 to 53, wherein the cells comprise leukocytes, stem cells, and / or fibroblasts.

55. 55. The method of claim 54, wherein the stem cells comprise mesenchymal stem cells.

56. A migrasome produced by the method according to any one of claims 1 to 55.

57. A migrasome produced in vitro or ex vivo, the migrasome having a size of about 50 nm to about 8000 nm.

58. 58. The migrasome of claim 57, produced in vitro from retraction fibers of cells.

59. A migrasome according to any one of claims 57 to 58, wherein the membrane of said migrasome is enriched with sodium / potassium ATPase and / or a functional fragment thereof.

60. A migrasome according to any one of claims 57 to 59, wherein the membrane of said migrasome is enriched with integrins and / or functional fragments thereof.

61. The migrasome according to any one of claims 57 to 60, wherein the membrane of said migrasome is enriched with a tetraspanin protein, a functional variant thereof, and / or a functional fragment thereof.

62. The migrasome of any one of claims 57 to 61, wherein the membrane of the migrasome is enriched with cholesterol.

63. The migrasome of any one of claims 57 to 62, wherein the migrasome is enriched in membrane microdomains.

64. The migrasome of any one of claims 57 to 63, wherein the migrasome content is at least partially reduced or absent compared to native migrasomes produced by the corresponding cell.

65. 65. The migrasome of claim 64, wherein the partially reduced contents comprises intraluminal vesicles.

66. Use of migrasomes in the delivery of exogenous cargo.

67. The use according to claim 66, wherein the migrasome comprises a migrasome according to any one of claims 57 to 65.

68. A delivery system comprising a migrasome and one or more exogenous cargoes.

69. 69. The delivery system of claim 68, wherein the exogenous cargo is directly or indirectly incorporated, conjugated or intercalated into the membrane and / or interior of the migrasome.

70. 70. The delivery system of any one of claims 68 to 69, wherein the migrasome comprises a migrasome of any one of claims 57 to 65.

71. A delivery system according to any one of claims 68 to 70, wherein the migrasome is derived from a cell.

72. A delivery system according to any one of claims 68 to 71, wherein the exogenous cargo comprises one or more targeting agents and / or therapeutically active agents.

73. 73. The delivery system of any one of claims 68 to 72, wherein the exogenous cargo comprises a protein, a lipid, a polynucleotide, a small molecule compound, a complex, a polysaccharide, a polymer, a nanoparticle, a microparticle, and / or an organelle.

74. 74. A delivery system according to any one of claims 68 to 73, wherein the exogenous cargo comprises a membrane protein, a soluble protein and / or a polypeptide.

75. A delivery system according to any one of claims 68 to 74, wherein the exogenous cargo comprises DNA and / or RNA.

76. 76. The delivery system of any one of claims 68 to 75, wherein the exogenous cargo comprises an antibody or antigen-binding antibody fragment thereof, an integrin or fragment thereof, an immunogenic protein, a cytokine, a chemokine, a receptor protein or fragment thereof, an enzyme, a tumor suppressor gene product, an siRNA, a microRNA, an antisense oligonucleotide (ASO), an mRNA, DNA, a gene editing tool, and / or a cytotoxic agent.

77. 77. A delivery system according to any one of claims 68 to 76, wherein the exogenous cargo comprises a PAMP, a DAMP, CD47, CD24, IL-12, IL-15, coagulation factor VII, coagulation factor VIII, coagulation factor IX, and / or a functionally active fragment thereof.

78. 78. The delivery system of any one of claims 68 to 77, wherein the exogenous cargo is directly or indirectly incorporated into the migrasome by gene editing, exogenous expression, liquid-solid conversion, membrane fusion, charge adsorption, physical adsorption, and / or chemical binding.

79. 79. A delivery system according to any one of claims 68 to 78, wherein the exogenous cargo is incorporated or intercalated into the migrasome by direct or indirect conjugation to a membrane component of the migrasome.

80. 80. The delivery system of claim 79, wherein the membrane components of the migrasomes include membrane proteins, cholesterol, phospholipids, carbohydrate chains on glycoproteins, and / or polysaccharides.

81. The delivery system of any one of claims 79 to 80, wherein the indirect conjugation comprises binding via click chemistry.

82. 82. The delivery system of any one of claims 79 to 81, wherein the indirect conjugation comprises providing the exogenous cargo conjugated to a first member of a binding pair and contacting the exogenous cargo with the migrasome, the membrane of the migrasome comprising a second member of the binding pair, the first member being capable of binding to the second member.

83. 83. The delivery system of claim 82, wherein the first and second members of the binding pair are selected from an antigen and its antibody; a receptor and its ligand; biotin and avidin; HaloTag and its ligand; and CP05 and CD63.

84. 84. A delivery system according to any one of claims 68 to 83, wherein the exogenous cargo is expressed as a membrane protein on the inner or outer surface of the membrane of the migrasome.

85. 85. A delivery system according to any one of claims 68 to 84, wherein the exogenous cargo is expressed on the inner or outer membrane surface of the migrasome as a fusion protein fused to a membrane protein or portion thereof.

86. 86. The delivery system of any one of claims 68 to 85, wherein the exogenous cargo is expressed on the inner or outer membrane of the migrasome as a fusion protein fused to a membrane protein or portion thereof by gene editing and / or exogenous expression.

87. A method of making a delivery system comprising providing a migrasome and loading said migrasome with an exogenous cargo.

88. 88. The method of claim 87, wherein the migrasome is an isolated or purified migrasome.

89. 89. The method of any one of claims 87 to 88, wherein loading the migrasome with an exogenous cargo comprises directly or indirectly incorporating or intercalating the exogenous cargo into the membrane and / or interior of the migrasome.

90. 90. The method of any one of claims 87 to 89, further comprising isolating or purifying said migrasome from a cell.

91. 91. The method of any one of claims 87 to 90, comprising providing a complex of the exogenous cargo and a first member of a binding pair, causing a cell to produce migrasomes comprising a second member of the binding pair, and contacting the migrasomes with the complex to form the delivery system.

92. The method of any one of claims 87 to 91, wherein the migrasome comprises a migrasome according to any one of claims 57 to 65.

93. The method of any one of claims 87 to 92, wherein the migrasome is derived from a cell.

94. 94. The method of any one of claims 87 to 93, wherein the exogenous cargo comprises one or more targeting agents and / or therapeutically active agents.

95. 95. The method of any one of claims 87 to 94, wherein the exogenous cargo comprises a protein, a lipid, a polynucleotide, a small molecule compound, a complex, a polysaccharide, a polymer, a nanoparticle, a microparticle, and / or an organelle.

96. 96. The method of any one of claims 87 to 95, wherein the exogenous cargo comprises a membrane protein, a soluble protein, and / or a polypeptide.

97. 97. The method of any one of claims 87 to 96, wherein the exogenous cargo comprises DNA and / or RNA.

98. 98. The method of any one of claims 87 to 97, wherein the exogenous cargo comprises an antibody or antigen-binding antibody fragment thereof, an integrin or fragment thereof, an immunogenic protein, a cytokine, a chemokine, a receptor protein or fragment thereof, an enzyme, a tumor suppressor gene product, an siRNA, a microRNA, an antisense oligonucleotide (ASO), an mRNA, DNA, a gene editing tool, and / or a cytotoxic agent.

99. 99. The method of any one of claims 87 to 98, wherein the exogenous cargo comprises a PAMP, a DAMP, CD47, CD24, IL-12, IL-15, coagulation factor VII, coagulation factor VIII, coagulation factor IX, and / or a functionally active fragment thereof.

100. 100. The method of any one of claims 87 to 99, wherein the exogenous cargo is directly or indirectly incorporated into the migrasome by gene editing, exogenous expression, liquid-solid conversion, membrane fusion, charge adsorption, physical adsorption, and / or chemical binding.

101. 101. The method of any one of claims 87 to 100, wherein the exogenous cargo is incorporated or intercalated into the migrasome by direct or indirect conjugation to a membrane component of the migrasome.

102. 102. The method of claim 101, wherein the membrane components of the migrasomes include membrane proteins, cholesterol, phospholipids, carbohydrate chains on glycoproteins, and / or polysaccharides.

103. The method of any one of claims 101 to 102, wherein the indirect conjugation comprises binding by click chemistry.

104. 104. The method of any one of claims 101 to 103, wherein the indirect conjugation comprises providing the exogenous cargo conjugated to a first member of a binding pair and contacting the exogenous cargo with the migrasome, the membrane of the migrasome comprising a second member of the binding pair, the first member being capable of binding to the second member.

105. 105. The method of claim 104, wherein the first and second members of the binding pair are selected from an antigen and its antibody; a receptor and its ligand; biotin and avidin; HaloTag and its ligand; and CP05 and CD63.

106. 106. The method of any one of claims 87 to 105, wherein the exogenous cargo is expressed as a membrane protein on the inner or outer surface of the membrane of the migrasome.

107. 107. The method of any one of claims 87 to 106, wherein the exogenous cargo is expressed on the inner or outer membrane surface of the migrasome as a fusion protein fused to a membrane protein or portion thereof.

108. A method of producing a delivery system, comprising: expressing an mRNA in a cell; causing the cell to produce a migrasome comprising an mRNA-binding protein; and binding the mRNA to the migrasome via the mRNA-binding protein.

109. A method of producing a delivery system, comprising: causing a cell to express an exogenous cargo on its cell membrane; and causing the cell to produce migrasomes comprising the exogenous cargo.

110. The method of claim 109, wherein the exogenous cargo is a protein.

111. 111. The method of claim 110, wherein the protein is a membrane protein.

112. The method according to any one of claims 110 to 111, wherein the protein is a soluble protein and is fused to a membrane protein or part thereof to form a fusion protein.

113. A composition comprising a migrasome according to any one of claims 57 to 65, or a delivery system according to any one of claims 68 to 86.

Citation Information

Patent Citations

  • Composition capable of modulating immune cell migration and method thereof

    CN111197057A

  • NOVEL HEAT SHOCK PROTEIN 20-RELATED POLYPEPTIDES AND USES THEREOF

    JP2007508823A

  • Methods for cancer prognosis

    JP2020530097A